

## Curriculum Vitae

**Date Prepared:** April 20, 2021

**Name:** Gabriel Dan Duda

**Office Address:** Massachusetts General Hospital (MGH)  
CNY 3.407, 149 Thirteenth Street, Charlestown, MA 02129

**Home Address:** 52 Unity Avenue, Belmont, MA 02478, USA

**Work Phone:** 1 (617) 726-4648

**Work Email:** [duda@steele.mgh.harvard.edu](mailto:duda@steele.mgh.harvard.edu), [gduda@partners.org](mailto:gduda@partners.org), [duda@iasgo.org](mailto:duda@iasgo.org)

**Work FAX:** 1 (617) 726-1962

**Place of Birth:** Iasi, Romania

### Education:

09/93	D.M.D.	Dentistry	University of Medicine Iasi, Romania
03/01	Ph.D.	Medical Science (Gastrointestinal Surgery) Thesis advisor: Makoto Sunamura, MD, PhD	Tohoku University Graduate School of Medicine, Japan

### Postdoctoral Training:

05/01- 06/04	Fellow	Tumor Biology (Rakesh K. Jain, PhD)	Steele Laboratories for Tumor Biology, Department of Radiation Oncology, MGH/HMS, Boston, MA
-----------------	--------	--	--

### Faculty Academic Appointments:

09/95- 03/01	University Preparatory	Dental Prosthetics	University of Medicine Iasi, Romania
06/04- 04/07	Instructor	Radiation Oncology	HMS, Boston, MA
05/07- 09/12	Assistant Professor	Radiation Oncology	HMS, Boston, MA
10/12-	Associate Professor	Radiation Oncology	HMS, Boston, MA

### Appointments at Hospitals/Affiliated Institutions:

02/94-01/95	Physician-in-training	Rotations in Orthodontics, Dental Prosthetics, and Oral Surgery	St. Spiridon University Hospital, Iasi, Romania
02/95-09/95	Staff Physician	Oral Surgery	Harlau Municipal Hospital, Romania
10/95-09/97	Resident in Dentistry	Department of Dental Prosthetics and Propedeutics	University Hospital Dental Clinic, Iasi, Romania
05/01-05/04	Research Fellow	Department of Radiation Oncology	MGH, Boston, MA
06/04-06/07	Assistant in Biology	Department of Radiation Oncology	MGH, Boston, MA
07/07-02/12	Assistant Biologist	Department of Radiation Oncology	MGH, Boston, MA
03/12-09/16	Associate Investigator	Department of Radiation Oncology	MGH Research Institute, Boston, MA
09/16-	Investigator	Department of Radiation Oncology	MGH Research Institute, Boston, MA

**Other Professional Positions:**

2007	Consultant	Takeda Pharmaceuticals, Chicago, IL	
2009	Consultant	Bridge Scientific Consulting LLC	
2009	Think Tank Participant	Forbeck Forum “The Biology and Treatment of Primary Brain Tumors”, Hilton Head Island, SC	
2012	Expert Panel Member	Renal Cell Carcinoma Expert Summit, Washington, DC (Angiogenesis Foundation)	
2013	Advisory Board Member	Hexal-Sandoz (Novartis), Zurich, Switzerland	
2015	Advisory Board Member	The Antibody-Drug Conjugates Conference, Boston	
2015-	Secretary General	IASGO	2% (5.3 days/year)
2016	Advisory Board Member 2016-2017	Bayer Medical Affairs Oncology Advisory Board for Cancer Immunotherapy	

2017	Advisory Board Member	Tilos Therapeutics, Inc., Cambridge, MA
2017	Consultant	twoXAR, Inc., San Francisco, CA
2018	Meeting Chair	The 1st Scientific Data Education Steering Committee (SDESC) Meeting, Bayer, San Francisco, CA
2019	Consultant	Simcere, Inc., Nanjing, China

### **Major Administrative Leadership Positions:**

#### **Local**

2016	Chairman of the Organizing Committee	The Special Scientific Symposium in honor of Professor Rakesh K. Jain, Laureate of the US National Medal of Science
2016–	Director of Translational Research in GI Radiation Oncology	Massachusetts General Hospital, Department of Radiation Oncology

#### **National**

2011	Leader, Workshop: Tumor angiogenesis as a therapeutic target	2011 Biorbis World Anti-Angiogenesis Summit, Boston, MA
2013	Chair Mini-Symposium: Novel Mediators of Tumor Angiogenesis	The 104th AACR Annual Meeting, Washington, DC
2019–	Course Director	Mayo Clinic Pancreatic and Hepato-Biliary Cancer Symposium, Mayo Clinic, Las Vegas, NV
2019	Advisory Board Member 2019–2024	MD Anderson Cancer Center Hepatocellular Carcinoma SPORE, Houston, TX

#### **International**

2013	Workshop Co-Director	International Workshop Translational imaging in gastroenterology and surgery, Craiova, Romania
2013	Head, Cancer Research section 2013–	IASGO
2017	ESF College of Expert Reviewers Member	European Science Foundation
2017	Conference Chair	The 1st CME IASGO International Symposium, Luzhou, China

2019	Conference Director	The 1st CME IASGO International Course, Braga, Portugal
2019	Conference Chair	The 2nd CME IASGO International Symposium, Luzhou, China
2020	Conference Chair	Webinar: HCC – What’s Next? Onco-Surgery Days Webinar Series, Istanbul, Turkey - IASGO
2021	Conference Chair	The 2021 IASGO GI Summit, Taipei, Taiwan

**Committee Service:**

**Local**

2016	The One Hundred Selection Committee Member 2016–2017	MGH Cancer Center
2017	Committee Member 2017–	Radiation Oncology Immuno-Oncology Working Group, MGH
2017	Organizing Committee Member and Chair of Session: Immunotherapy 2017	2017 Boston Angiogenesis Meeting
2018	Organizing Committee Member 2018	Vascular Biology Seminar Series, Harvard Medical School

**National**

2010–	RTOG 0837 / ACRIN 6689 Study Planning (weekly teleconference) 2010–2012	RTOG, USA Committee Member
2016–	NRG Oncology / NRG-GI003 Phase III Study (weekly teleconference) 2016–2021	NRG Oncology, USA Translational Co-Chair
2017–	NCI Pancreatic Cancer Microenvironment Network (PaCMEN) (monthly teleconference) 2017–2022	US NIH, NCI Associate member
2020–	NCI Hepatobiliary Task Force for Immuno-Oncology Biomarkers, 2020–2021	US NIH, NCI Member

**International**

2015	PhD Defense, Annique MMJ Pieters Duyverman, Mentor, Prof. Borel Rinkes January 2015	Assessment Committee Member and co-Mentor, University of Utrecht, The Netherlands
2015	PhD Defense, Elizabeth Kuczynski, Mentor, Prof. Robert Kerbel October 2015	Oral Examination Committee Member, School of Graduate Studies, University of Toronto, Canada
2021	PhD Defense, Rakesh R. Ramjiawan, Mentors, Prof. Arjan Griffioen and Dan G. Duda	Assessment Committee Member and Mentor, VU University, Amsterdam, The Netherlands

2021	TBD PhD Defense, Nisha Gupta, Mentor, Prof. Prof. Victor van Hinsbergh TBD	Assessment Committee Member and Co-Mentor, VU University, Amsterdam, The Netherlands
------	--	--

**Professional Societies:**

2000– 2000–2021 2013	American Association for Cancer Research	Active member Organizer and Chair, Mini-Symposium: <i>Novel Mediators of Tumor Angiogenesis</i> , 104 <sup>th</sup> AACR Annual Meeting, Washington, DC
2005– 2005–2008	International Society for Stem Cell Research	Active member
2006– 2006–2021 2010	American Society of Clinical Oncology	Active-allied member Discussant ( <i>Developmental / Experimental Therapeutics</i> Track), 2010 ASCO Annual Meeting, Chicago, IL
2007– 2007–2010	North America Vascular Biology Organization	Member
2007– 2007–2021 2013–2021 2014–2021 2014  2015  2015  2015–2021 2016  2017  2017  2018  2019	International Association of the Surgeons, Gastroenterologists and Oncologists	Permanent Member Head, Research Section Coordinator, Educational Programs Scientific Committee Member, 24 <sup>th</sup> World Congress of IASGO, Vienna, Austria Scientific Committee Member, 4 <sup>th</sup> IASGO International Meeting, Moscow, Russia Scientific Committee Member, the 25 <sup>th</sup> World Congress of IASGO, Fuzhou, China Secretary General Organizing Committee Member, 26 <sup>th</sup> World Congress of IASGO, Seoul, Korea Organizing Committee Member, 27 <sup>th</sup> World Congress of IASGO, Lyon, France The 1 <sup>st</sup> CME IASGO Symposium, “Current and Future Perspectives in Primary Liver Tumors”, Rotterdam, The Netherlands Organizing Committee Member, 28 <sup>th</sup> World Congress of IASGO, Moscow, Russia Organizing Committee Member, 29 <sup>th</sup> World Congress of IASGO, Bangkok, Thailand

	2021	Organizing Committee Member, 32 <sup>th</sup> World Congress of IASGO, Taipei, Taiwan
2009–	DF/HCC Angiogenesis Invasion and Metastasis 2009–2017	Member
2009–	Harvard Catalyst Tumor Microenvironment Research Group 2009–2021 2012	Member Harvard Catalyst Program Grant Reviewer
2011–	The New York Academy of Sciences 2011–2015	Active Member
2012–	American Association for the Study of Liver Diseases 2012–2021 2019–2021	Member Liver Fibrosis Special Interest Group (SIG), Global Outreach Subcommittee
2016–	American Gastroenterological Association 2016–2017	Member
2017–	American Association for the Advancement of Science 2017–2021	Member
2017–	Microcirculation Society 2017–2021	Member
2017–	European Society for Medical Oncology 2017–2018	Member
2019–	American Institute for Medical and Biological Engineering 2019–2021 2020	Member Inducted in the College of Fellows
2020–	Society for Immunotherapy of Cancer 2020–2021	Member

**Grant Review Activities:**

2006–	Cancer Research Section 2006 2018	Hong Kong Research Council Ad hoc grant reviewer Ad hoc grant reviewer
2006–	Cancer Research Section 2006	United Kingdom Research Council Ad hoc grant reviewer
2008–	Cancer Research Section  2008–2021	Italian Association for Cancer Research (AIRC) Ad-hoc grant reviewer
2008–	Cancer Research Section 2008 2016	Cancer Research UK Ad hoc grant reviewer Ad hoc grant reviewer

2009–	ARRA RC1 Challenge Grant – ZRG1 OTC-K (58) Section 2009	NIH  Ad hoc member
2009–	SBIR/STTR – Cancer Drug Development and Therapeutics (CDDT) Study Section 2009–2015	NIH  Ad hoc member
2010–	Drug Discovery and Molecular Pharmacology (DMP) Study Section 2010–2011 2012–2018 2013, 2018	NIH  Ad hoc member Permanent member Co-Chair
2010–	Biomedical Research Program 2010	Institut National du Cancer France Ad hoc reviewer
2011–	Austrian Science Fund 2011	Austria Ad hoc grant reviewer
2011–	Med4 Study Section  2011–2014 2015–2020 2019–2020	Research Foundation Flanders (FWO) , Belgium Ad hoc grant reviewer Permanent member Chair
2011–	Pennsylvania Department of Health 2011–2018	State of Pennsylvania Ad hoc grant reviewer
2012–	Romanian National Development and Innovation Council	Romania
2012–	Membrane Biology and Protein Processing (MBPP) Study Section 2012	NIH  Ad hoc member
2012–	Grant Review Panel 2012	US-Israel Binational Science Foundation Ad hoc grant reviewer
2012–	National Institute of Social Care and Health Research 2012	Wales  Ad hoc grant reviewer
2012–	Institutional grants  2012	Duke University Medical Center/VARIAN Medical Systems Ad hoc grant reviewer
2013–	SwissTransMed 2013	Switzerland Ad hoc grant reviewer
2013–	Joint Research Actions 2013 2015	Liège University, Belgium Ad hoc grant reviewer Ad hoc grant reviewer
2014–	Tumor Biology and Genomics (TBG) Section 2014–2015 2016–2020	American Cancer Society  Ad hoc member Permanent member
2014–	SBIR – Small Business: Molecular Analysis Technology Study Section 2014–2015	NIH  Ad hoc member

	2014–2015	Co-Chair
2014–	Clinical Trial Planning Grant Study Section	NIH
	2014	Ad hoc member
	2016	Ad hoc member
2014–	Special Emphasis Panel (SEP #12; R03 and R21 Omnibus)	NIH
	2014–2016	Ad hoc member
2014	Research Grants	Swiss National Science Foundation
	2014	Ad hoc member
	2018	Ad hoc member
2014–	Florida Bankhead-Coley Cancer Research Program	State of Florida
	2014–2021	Ad hoc member
2015–	Breast Cancer Now	UK
	2015	Ad hoc grant reviewer
2016–	National Cancer Institute Special Emphasis Panel	NIH
	2016	Ad hoc member
2016–	SPORE 1 Special Emphasis Panel	NIH
	2016–2021	Ad hoc member
2017–	Cancer Research Section	European Science Foundation
	2017–2020	Ad hoc grant reviewer
2017–	Merit Review Oncology Panel	US Department of Veterans Affairs
	2017	Ad hoc member
	2020	Ad hoc member
2018–	Research Competitiveness Program	American Association for the Advancement of Science
	2018–2020	Ad-hoc grant reviewer
2018–	Research Project	University of Sharjah, UAE
	2018	Ad hoc grant reviewer
2019–	Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21) Panel	NIH
	2019	Ad hoc member
2019–	US-China Program for Biomedical Collaborative Research Study Section	NIH
	2019	Ad hoc member
2019–	Interim Support Funding Program	MGH ECOR
	2018–2021	Ad hoc member
2019–	Research Grants	Dutch Cancer Society
	2019	Ad hoc reviewer
2019–	Research Council	KU Leuven, Belgium
	2019	Ad hoc reviewer
2019–	Loeffler Team Science Seed Funding Program	MGH Radiation Oncology
	2019–2021	Ad hoc member



2019– 2019	SEP U01 Grant Review Panel	NIH Ad hoc member
2019– 2019–2020 2019 2020	Cancer Biotherapeutics Development (CBD) Study Section	NIH Ad hoc member Co-Chair Chair
2019– 2019–2020	ACS Institutional Grant Pilot Funding Program	MGH Ad hoc member
2020– 2020	StandUp2Cancer Pediatric Cancer Review Panel	Research Foundation Flanders (FWO), Belgium Ad hoc reviewer
2020– 2020	Development Research Project (DRP) Award Review Panel	MD Anderson Cancer Center SPORE Ad hoc member
2021– 2021	Rare Cancers Research Program (RCRP) Review Panel	Department of Defense Ad hoc member

#### **Editorial Activities:**

- **Ad hoc Reviewer**

*Angiogenesis*  
*Anticancer Therapy*  
*ASCO Annual Meeting and ASCO Educational Book*  
*BioMedCentral Cancer*  
*Blood*  
*British Journal of Cancer*  
*British Journal of Surgery*  
*Cancer Cell*  
*Cancer Drug Resistance*  
*Cancer Research*  
*Cancers*  
*Cancer Treatment Reviews*  
*Carcinogenesis*  
*Cell Communication and Signaling*  
*Cell Cycle*  
*Cellular & Molecular Immunology*  
*Clinical Cancer Research*  
*Clinica Chimica Acta*  
*Current Opinion in Investigational Drugs*  
*CNS Drugs*  
*Cytokine*  
*EMBO*  
*EMBO Medicine*  
*EBioMedicine*

*Endothelium*  
*European Journal of Cancer*  
*Expert Opinion on Drug Safety*  
*Expert Review of Anticancer Therapy*  
*Gastroenterology*  
*Gut*  
*Hepatology*  
*Hepatoma Research*  
*International Journal of Cancer*  
*International Journal of Radiation Biology*  
*International Journal of Radiation Oncology Biology & Physics*  
*Investigational New Drugs*  
*Journal of Cellular and Molecular Medicine*  
*Journal of Clinical Investigation*  
*Journal of Clinical Oncology*  
*Journal of Experimental & Clinical Cancer Research*  
*Journal of Hepatology*  
*Journal of Hepatology Reports*  
*Journal of ImmunoTherapy for Cancer*  
*Journal of Pathology*  
*Journal of Vascular Research*  
*Molecular Cancer Therapeutics*  
*Nanomedicine*  
*Nature Reviews Cancer*  
*Nature Reviews Clinical Gastroenterology and Hepatology*  
*Nature Reviews Clinical Oncology*  
*npj Nature Precision Oncology*  
*Neuro-Oncology*  
*Oncogene*  
*Oncologist*  
*Oncotarget*  
*Pharmacology and Therapeutics*  
*PLoS One*  
*Proceedings of the National Academy of Science U S A*  
*Regenerative Medicine*  
*Science*  
*Scientific Reports*  
*Surgical Oncology*  
*Trends in Endocrinology and Metabolism*

• **Other Editorial Roles**

2010–	Editorial Board Member	<i>American Journal of Cancer Research</i>
2013–2015	Editorial Board Member	<i>Hepatogastroenterology</i>
2013–	Senior Editor	<i>Discoveries</i>
2015–	Founding Editor	<i>Surgery, Gastroenterology and Oncology</i>

2015	Guest Editor Theme Issue	<i>The Cancer Journal</i>
2016–	Consultant Editor	<i>Digestive Surgery</i>
2016–	Editorial Board Member	<i>Clinical &amp; Translational Radiation Oncology</i>
2017–	Editorial Board Member	<i>Journal of Hepatocellular Carcinoma</i>
2018	Guest Editor Theme Issue	<i>Surgery, Gastroenterology and Oncology</i>
2019–	Associate Senior Editor	<i>International Journal of Radiation Oncology*Biology*Physics</i>
2020–	Editorial Board Member	<i>Cancers</i>
2021	Co-Editor with M. Makuuchi, N. Kokudo, I. Popescu, J. Belghiti, H.-S. Han, and K. Takaori	<u>IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases</u> . 1 <sup>st</sup> Edition; Springer-Nature.

### Honors and Prizes:

1997	<i>Monbusho Fellowship</i>	Japanese Government	Research
1998	<i>Young Investigator Award</i>	International Association of Pancreatology	Research
2001	<i>Scholar-in-Training Award</i>	Ito-En and American Association for Cancer Research (AACR)	Research
2006	<i>Scholarship</i>	European Commission Marie Curie Actions Programme	Research
2007	<i>Team Science Award</i>	MGH Clinical Research	Research
2007	<i>Keynote Speaker</i>	The 5 <sup>th</sup> IBC Life Sciences Meeting on Anti-Angiogenesis, Boston	Research
2007	<i>Research Team Award</i>	Douglass Family Foundation, MA	Research
2008	<i>Junior Investigator Award Finalist</i>	North America Vascular Biology Organization	Research
2009	<i>Early Career Oncologists / Scientists (ECOS) Award</i>	EORTC-NCI-ASCO	Research
2010	<i>Lucien J. Rubinstein Team Award</i>	American Association of Pathologists	Research
2012	<i>Honorary Member</i>	Academy of Medical Sciences of Romania	Research and service
2014	<i>Gerritsen Award</i>	The Microcirculatory Society	Research
2014	<i>Capussotti Award</i>	IASGO	Research
2014	<i>Keio University Lecture</i>	Keio University Tokyo, Japan	Research
2014-16	<i>Fellow</i>	Andrew L. Warshaw, M.D., Institute for Pancreatic Cancer	Research

2015	<i>Keynote Speaker</i>	The 14 <sup>th</sup> International Wolfsberg/ ESTRO Radiation Biology Meeting	Research
2015	<i>Tohoku Medical Society Lecture</i>	Tohoku University Sendai, Japan	Research
2015	<i>Keynote Lecture</i>	Neuroononcology Group (NOA) Winterschool Freiburg, Germany	Research
2015	<i>Honoree of the One Hundred</i>	Mass General Cancer Center	Research and service
2016	<i>Heroes of Hope Award</i>	Granara-Skerry Trust	Research and service
2016	<i>State-of-the-art Lecture</i>	IASGO World Congress, Korea	Research
2017	<i>Plenary Lecture</i>	Hong Kong International Oncology Forum 2017 (HKIOF 2017)	Research
2017	<i>Partners HealthCare Innovator Award</i>	Partners HealthCare, Boston	Research
2017	<i>Keio Medical Society Lecture</i>	Keio University Tokyo, Japan	Research
2018	<i>IASGO Achievement Award</i>	30 <sup>th</sup> Anniversary of IASGO	Research
2018	<i>Excellence Award on the occasion of the 100<sup>th</sup> Anniversary of Unification of the Romanian State</i>	Romanian-American Chamber of Commerce	Research and service
2019	<i>Partners HealthCare Innovator Award</i>	Partners HealthCare, Boston	Research
2020	<i>Doctor Honoris Causa</i>	University of Medicine Iasi, Romania	Research
2020	<i>Induction into the College of Fellows – Class of 2020</i>	American Institute for Medical and Biological Engineering (AIMBE)	Research and service
2020	<i>2020 Excellence Award – World Ambassador of Romanian Medicine</i>	Romanian Academy and Medica Academica, Tarus Media	Research and service

## **Report of Funded and Unfunded Projects**

### **Past**

2003–2005 *Angiogenic Profile of Rectal Cancer* (PI, Willett)  
National Cancer Institute / R21CA099237  
Co-Investigator  
The major goal of this study was to evaluate changes in tumor vasculature and in angiogenic markers after antiangiogenic therapy with bevacizumab in rectal cancer patients.

- 2005–2007 *Characterization of Circulating Endothelial Cells and Progenitor Cells as a Surrogate Marker for Progression and Treatment of Solid Tumors* (PI, Duda)  
AACR-Genentech BioOncology Career Development Award  
PI (\$102,000)  
The goal of the study was to identify the origin and phenotype of endothelial and progenitor cells in tumor-bearing mice and study their kinetics after antiangiogenic therapies.
- 2005–2009 *Identification and Validation of Surrogate Markers for Response and Vascular Normalization after VEGF Blockade in Colorectal Cancer Patients* (PI, Jain)  
National Foundation for Cancer Research / Research Award  
Co-Investigator  
The goals of the proposed studies were to determine the mechanism of action and identify biomarkers for bevacizumab in rectal cancer patients
- 2005–2007 *Phase II study of AZD2171 in patients with recurrent glioblastoma* (PI, Batchelor)  
National Cancer Institute / R21CA117079  
Co-Investigator  
The goal of this study was to assess the efficacy and safety of AZD2171 in rGBM patients.
- 2006–2008 *Phase II trial of AZD2171 monotherapy in recurrent head-and-neck cancer* (PI, Rocco)  
National Cancer Institute / R21CA099237  
Co-Investigator  
The major goal of this study was to evaluate changes in tumor vasculature and in angiogenic markers after antiangiogenic therapy with bevacizumab in rectal cancer patients
- 2006–2018 *Integrative Pathophysiology of Solid Tumors* (PI, Jain)  
National Cancer Institute / P01CA080124  
Project Co-Leader (2006-2011) and Project Leader (2012-2017) (\$767,294)  
The overall goal of this program project is to identify common and disease-specific tumor stroma-mediated pathways of resistance to standard therapies in glioma (Project 1), colorectal cancer (Project 2), HCC (Project 3), and pancreatic cancer (Project 4). Project 3 is dedicated to studies of the role of CXCR4 and ERK in HCC evasion from sorafenib.
- 2006–2011 *Role of BMDCs in Solid Tumor Growth and Relapse* (PI, Jain)  
National Cancer Institute / R01CA115767  
Co-Investigator  
The goal of this grant was to characterize the kinetics, phenotype and function of bone marrow-derived cells and the roles of VEGFR1 and CXCR4 in growing and treated tumors.
- 2007–2019 *Angiogenesis-targeting Therapy for Glioblastoma* (PI, Batchelor)  
National Cancer Institute / 2R01CA129371  
Co-Investigator  
The goal of this project is to assess biomarkers of response and escape of standard antiangiogenic therapy with bevacizumab in glioblastoma patients.
- 2008–2009 *Bone Marrow Stromal Cell Characterization for Immunotherapy for Tumors* (PI, Duda)  
National Cancer Institute / Federal Share Proton Beam Income Program Grant  
PI (\$77,220)  
The major goals of this study characterize a population of precursors cells that can be expanded, modified genetically, and then adoptively transferred to tumors to enhance anti-tumor immune responses
- 2008–2010 *A Phase II Study of Blood Circulating Cells and Plasma Angiogenic Proteins as Biomarkers of Anti-VEGF Therapy with Bevacizumab in Sarcoma Patients* (PI, Duda)  
MGH / Ira J. Spiro Translational Research Award  
PI (\$50,000)

- The goal of this study is to provide strong candidate biomarkers of response – to be evaluated in future randomized trials of antiangiogenic agents in sarcoma patients.
- 2008–2013 *Murine Circulating Endothelial Precursors (CEPs) and Lung Capillary Repair* (PI, Jones)  
NHLBI / R01 HL089252  
Co-Investigator  
The major goals of this study are to evaluate the roles of circulating precursor cells in lung capillary repair after hyperoxia-induced damage in mice. The emphasis is on detecting the CEP origin and the role of VEGF and SDF1 $\alpha$  signaling
- 2008–2013 *Probing Tumor Microenvironment Using Nanotechnology* (PI, Jain)  
National Cancer Institute / R01CA126642  
Co-Investigator (Project 3 Leader)  
This Bioengineering Research Partnership (BRP) is exploiting emerging advances in semiconductor nanocrystal-based biomedical imaging to probe the tumor microenvironment.
- 2009–2013 *Cellular and Molecular Biomarkers of GBM Resistance to Antiangiogenic Therapy* (PI, Jain)  
National Foundation for Cancer Research/Research Award  
Co-Investigator  
The goal of these clinical correlative studies is to explore in patients with glioblastoma the cellular and molecular determinants of resistance to antiangiogenic treatment
- 2009–2010 *Visualizing Immune Responses In Vivo: A Systems Biology Approach* (PI, Duda)  
MGH Executive Committee on Research (ECOR) / Formulaic Bridge Funding Grant  
PI (\$50,000)  
The goal of this study is to establish and utilize targeted nanocrystal immunoconstructs for *in vivo* cytometric analyses of immune cells in tumors during immunotherapy
- 2009–2011 *Visualizing Immune Responses In Vivo: A Systems Biology Approach* (PI, Duda)  
National Cancer Institute / R21CA139168  
PI (\$242,000)  
The goal of this study is to establish and utilize targeted nanocrystal immunoconstructs for *in vivo* cytometric and functional analyses of immune cells in tumors during immunotherapy.
- 2010–2012 *A Study of SDF1 $\alpha$ -CXCR4 as a Potential Mechanism of Distant Progression in Pancreatic Cancer after Neoadjuvant Chemoradiation* (PI, Duda)  
MGH / Ira J. Spiro Translational Research Award  
PI (\$50,000)  
The goal of this study is to provide strong candidate for anti-metastasis therapy in neoadjuvant setting in pancreatic carcinoma patients.
- 2010–2016 *Strategies for Personalized Treatment of Metastatic Breast Cancer* (PI, Jain)  
Department of Defense / Innovator Award (Breast Cancer Program) W81XWH-10-1-0016  
Co-Investigator  
The goal of this grant is to improve antiangiogenic therapy in metastatic breast cancer by optimizing the schedule of therapy, and identifying new targets and biomarkers of response
- 2011–2014 *CXCR4 Blockade as a Sensitizer in Bone Metastatic Prostate Cancer* (PI, Duda)  
American Cancer Society / Research Grant 120733-RSG-11-073-01-TBG  
PI (\$600,000)  
The goal of this proposal is to study the effects of CXCR4 blockade combined with radiation or chemotherapy and anti-VEGF therapy in bone metastatic prostate cancer models.
- 2011–2017 *Role of SDF1 $\alpha$  in Prostate Cancer Relapse and Metastasis Post-radiotherapy* (PI, Duda)  
National Cancer Institute / R01CA159258

- PI (\$933,750)  
The aim of this R01 grant is to study the role of SDF1 $\alpha$  /CXCR4 vs /CXCR7 pathway in prostate cancer after irradiation. The hypothesis tested is that blockade of SDF1 $\alpha$  pathway in locally advanced prostate cancer will increase local control and inhibit metastasis.
- 2011–2012 *Role of PIGF, VEGF and Ang2 in Medulloblastoma and Glioblastoma* (PI, Jain)  
Roche-sponsored / Research Grant  
Co-Investigator  
The goal of this study is to provide efficacy data and further mechanistic insight for PIGF inhibition in medulloblastoma and VEGF and Ang2 blockade in glioblastoma
- 2011–2013 *Role of SDF1 $\alpha$  in Prostate Cancer Relapse and Metastasis Post-radiotherapy* (PI, Duda)  
MGH / Ira J. Spiro Translational Research Award  
PI (\$50,000)  
The aim of this grant is to explore the role of SDF1 $\alpha$  pathway and inflammatory bone marrow-derived cells in prostate cancer patients after irradiation
- 2011–2013 *An Exploratory Study of SDF1 $\alpha$ /CXCR4 Pathway as a Potential Mechanism of Disease Progression in Patients with Liver Cancer after Proton Beam Therapy* (PI, Duda)  
National Cancer Institute / Proton Beam Federal Share Individual Grant  
PI (\$112,606)  
The goal of this study is to provide further rationale for CXCR4 inhibition as a radiosensitizer for the treatment of hepatocellular carcinoma patients with proton therapy.
- 2011–2013 *Novel Approaches to Anti-metastasis Therapy in Breast Cancer* (PI, Jain)  
National Cancer Institute / Proton Beam Federal Share Umbrella Grant  
Project 1 PI (\$636,504)  
The goal of this study is to study novel mechanisms of breast cancer metastasis and identify and test new targets for therapy. Project 1 will test the role of endothelial Fak/Src.
- 2013–2015 *Targeting HGF/c-MET Pathway to Improve Outcomes in Patients with PDAC* (PI, Zhu)  
Cummings Foundation – OneWorld Boston / Research Grant  
Co-Investigator  
The aim of this pilot grant is to target HGF/c-MET pathway with small molecule inhibitors to sensitize PDA to radiation, inhibit distant metastasis and improve outcomes.
- 2014–2016 *Cellular and Molecular Biomarkers of GBM Resistance to Antiangiogenic Therapy* (PI, Jain)  
National Foundation for Cancer Research Fellow / Award  
Co-Investigator  
The goal of these clinical correlative studies is to explore in patients with glioblastoma the cellular and molecular determinants of resistance to antiangiogenic treatment
- 2014–2017 *Specific roles of KRASG12D versus KRASG12R in pancreatic ductal adenocarcinoma progression and resistance to cytotoxics* (PI, Duda)  
Andrew L. Warshaw, M.D. Institute for Pancreatic Cancer Research / Pilot Grant  
PI (\$100,000)  
The aim of this pilot grant is to study the specific roles of KRASG12D versus KRASG12R mutations in pancreatic ductal adenocarcinoma.
- 2014–2017 *Blocking HGF to Overcome Radio- and Chemo-Resistance in pancreatic ductal adenocarcinoma* (PI, Duda)  
Merrimack Pharmaceuticals, Inc. / Sponsored Research Agreement  
PI (\$330,376)  
The aim of this pilot grant is to target HGF pathway with a dual c-MET/EpCAM antibody as a strategy to sensitize pancreatic ductal adenocarcinoma to cytotoxics.
- 2015–2018 *Translational Phase I studies of DKN-01 in refractory esophageal cancer and in cholangiocarcinoma patients* (PI, Duda)  
Leap Tx / Research Support

- PI (\$212,243)  
The goal of these correlative studies is to explore biomarkers of response and mechanisms of action for DKN-01, a humanized monoclonal antibody that targets the Dickkopf-1 (DKK1).
- 2016–2017 *Using dasatinib to target tumor growth and cirrhosis in HCC* (PI, Duda)  
MGH ECOR / Deliberative Interim Research Support  
PI (\$75,000)  
The goal of these studies is to examine the mechanism of action and efficacy of dasatinib in models of hepatocellular carcinoma and liver cirrhosis in mice.
- 2016–2019 *Using anti-CXCR4 antibodies to facilitate anti-PD1 immunotherapy in HCC models* (PI, Duda)  
Bristol Myers Squibb / Sponsored Research Agreement  
PI (\$225,033)  
The focus of this grant is on the use orthotopic murine models of HCC to examine the therapeutic benefit of antibody blockade of PD-1 with or without CXCR4 blockade.
- 2017–2018 *Redirected Immunotherapy with Ra223 for Metastatic Prostate Cancer* (MPIs, Duda/Cobbold)  
MGH ECOR / Deliberative Interim Support Funding  
PI (\$75,000)  
The aim of this grant is to develop a new immunotherapy approach for bone metastatic prostate cancers using antibody-peptide conjugates (APEC) with radium treatment.
- 2017–2018 *Development, Characterization & Commercialization of a Viable Frozen Patient-Inclusive Hepatocellular Carcinoma Tumor Bank* (PI, Duda/Briggs)  
National Cancer Institute / R41CA213678  
MPI (\$60,556)  
The aim of this Phase I STTR grant is to develop in collaboration with Woodland Pharma a viable frozen patient-inclusive hepatocellular carcinoma tumor bank for in vivo and in vitro testing of new therapeutic agents.
- 2018–2019 *Biomarkers of response to cabozantinib in patients with NET* (MPIs, Chan/Duda)  
Neuroendocrine Tumor Research Foundation / Pilot Project Award  
MPI (\$100,000)  
The aims of this grant are to identify blood biomarkers that may predict efficacy of treatment with cabozantinib in neuroendocrine tumor (NET) patients.
- 2019–2020 *Vascularized tumor explants for drug testing* (MPIs, Duda/Munn)  
MGH ECOR / Formulaic Interim Support Funding  
MPI (\$75,000)  
The aim of this grant is to develop a new ex vivo tissue biomimetic methodology for drug testing for pancreatic ductal adenocarcinoma patients.
- 2019–2020 *Therapeutic modulation of the immune response in IDH mutant liver cancer* (MPIs, Duda/Willers)  
MGH ECOR / Deliberative Interim Support Funding  
PI (\$37,500)  
The aim of this grant is to leverage synergistic interdisciplinary expertise and complementary pre-clinical liver cancer models to deliver critically needed data that will validate the existence of increased biological effects of proton beam therapy in vivo, link increased proton RBE to a clinically relevant and testable tumor genotype, and facilitate the design of rational proton beam therapy combinations with immunotherapy.
- 2016–2021 *Alpharadin with anti-PD-1 therapy in metastatic prostate carcinoma models* (PI, Duda)  
Bayer / Sponsored Research Agreement  
PI (\$415,159)



2018–2021 The focus of this grant is on the use orthotopic murine models of bone metastatic prostate cancer to examine the therapeutic benefit of alpharadin using antibody blockade of PD-1. Developing Novel Approaches to Detect and Treat Early Pancreatic Cancer (PI, Ryan)  
AACR / SU2C-Lustgarten Foundation Pancreatic Cancer Interception Dream Team  
Co-Investigator  
The aim of this grant is to conduct a randomized phase II and biomarker study of an anti-fibrotic agent with or without immune checkpoint blockade to enhance the efficacy of cytotoxics for borderline and locally advanced PDAC.

## Current

2014–2022 Targeted Therapy of Pancreatic Cancer (PI, Duda)  
The Samuel Singer Brown Fund for Pancreatic Ductal Adenocarcinoma Research  
PI (\$233,374)  
The aim of this pilot grant is to target the MET pathway using crizotinib as a strategy to sensitize PDAC to cytotoxics to inhibit distant metastasis and improve outcomes.

2015–2022 Dissecting pediatric brain tumor microenvironment to improve treatment (PI, Jain)  
National Cancer Institute / R35 CA197743  
Co-Investigator  
The goal of this project is to gain new insights into pediatric TME to develop a program to further explore underlying mechanisms as well as other therapeutic opportunities to improve the outcome of chemo-radiation, targeted therapies and immunotherapies.

2016–2021 Rationally combining regorafenib with anti-PD1 immunotherapy in hepatocellular carcinoma models in mice with cirrhosis (PI, Duda)  
Bayer / Sponsored Research Agreement  
PI (\$309,583)  
The aim of this grant is to use orthotopic (grafted and genetically engineered) murine of HCC to examine the therapeutic benefit of regorafenib with PD-1 blockade.

2016–2021 Combining copanlisib with anti-PD1 immunotherapy in HCC models in mice (PI, Duda)  
Bayer / Sponsored Research Agreement  
PI (\$317,618)  
The focus of this grant is on the use orthotopic (grafted and genetically engineered) murine models of HCC to examine the therapeutic benefit of copanlisib with PD-1 blockade.

2017–2021 Using cabozantinib to modulate anti-tumor immunity and enhance the efficacy of immunotherapy in metastatic breast cancer and HCC models in mice (PI, Duda)  
Exelixis / Sponsored Research Agreement  
PI (\$351,835 total)  
The aim of this grant is to use cabozantinib as an immuno-modulator – in addition to anti-angiogenic and anti-metastatic agent – to potentiate the efficacy of immune checkpoint-based immunotherapy for metastatic breast cancer and HCC.

2017–2022 Reprogramming PDAC microenvironment to improve immunotherapy (MPI, Jain/Pittet)  
National Cancer Institute / U01CA224348  
Co-Investigator  
The aim of this grant is to develop anti-fibrotic agents to reprogram tumor microenvironment and enhance the efficacy of cytotoxics and immunotherapy for locally advanced PDAC.

2019–2021 Combination of p53 mRNA Nanotherapy with Immunotherapy for HCC Treatment (PI, Shi)  
DoD PRCRP / W81XWH1910482  
Subaward PI (\$148,971)

- The goal of this project is to use p53 mRNA nanotherapy to promote antitumor immunity against p53-deficient HCCs.
- 2019–2022 Role and biomarker value for plasma HGF in susceptibility to high-dose radiation-induced liver dysfunction (PI, Duda)  
DoD PRCRP / W81XWH-19-1-0284  
PI (\$1,000,000)  
The goal of this project is to validate plasma HGF as a biomarker of susceptibility to radiation induced liver dysfunction in liver cancer patients, and to gain new insights into how HGF/Met pathway mediates liver damage after radiation using mouse models.
- 2020–2021 Enhancing the Efficacy of dual PD-1/VEGFR2 Inhibition in HCC (PI, Duda)  
Bristol Myers Squibb / Sponsored Research Agreement  
PI (\$181,743)  
The focus of this grant is on the use orthotopic murine models of HCC to examine the therapeutic benefit of immunomodulating agents with dual anti-VEGFR/PD-1 therapy.
- 2021–2026 Dual blockade of VEGF and PD-L1 pathway in resectable HCC (MPI, Kaseb/Duda/Amin)  
NCI / 1R01CA260872-01  
MPI (\$726,250, subcontract to MDACC)  
The goal of the proposed research is to demonstrate the activity and investigate the mechanism of action of dual VEGF/PD-L1 blockade in resectable HCC patients.
- 2021–2026 Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy (MPI, Kumar/Duda)  
NCI / 1R01CA260857-01  
MPI (\$1,355,835)  
The goal of the proposed research is to optimize and investigate the detection of PD-L1 expression in TNBC models in mice during immunotherapy.

### Projects Submitted for Funding

- 2021–2022 Enhancing the Efficacy of dual PD-1/VEGFR2 Inhibition in Hepatocellular Carcinoma Using IL-27 Abs (PI, Duda)  
Surface Oncology / Sponsored Research Agreement  
PI (\$144,642)  
The focus of this grant is on the use orthotopic murine models of HCC to examine the therapeutic benefit of IL-27 blockade with dual anti-VEGFR/PD-1 therapy.
- 2021–2023 Radiation and CSPG4-specific CAR T cell based combinatorial therapy for the in vivo treatment of TNBC (MPI, Ferrone/Duda)  
NCI / 1R03CA256764-01A1  
Partnering PI (\$100,000)  
The goal of the proposed research is to demonstrate increased efficacy of novel CAR-T cells using radiotherapy and anti-PD-1 therapy in metastatic triple negative breast cancer.
- 2021–2024 Mechanisms Mediating the Immune Responses after Proton versus Photon Radiotherapy in IDH Mutant Liver Cancer (PI, Duda)  
DoD PRCRP / CA200082  
PI (\$500,000)  
The aim of this grant is to use liver cancer models to validate the increased biological effects of proton therapy in vivo and link the increased efficacy with to a clinically testable tumor genotype and facilitate the design of combinations with immunotherapy.
- 2021–2026 Vascularized tumor explants for drug testing (MPIs, Munn/Duda)  
NCI / 1R01CA247441-01A1  
MPI (\$1,250,000)

- The aim of this grant is to develop a new *ex vivo* tissue biomimetic methodology for drug testing for pancreatic ductal adenocarcinoma patients.
- 2022–2026 Mechanisms of increasing T cell infiltration and anti-PD-1 therapy efficacy in hepatocellular carcinoma using regorafenib or sorafenib (PI, Duda)  
NCI / 1R01CA264879-01A1  
PI (\$1,250,000)  
The goal of this project is to establish the mechanism of benefit of the combination of the anti-HCC drug regorafenib with anti-PD1 therapy.
- 2021–2023 Understanding the mechanisms of benefit and optimizing lenvatinib/anti-PD1 combination therapy using hepatocellular carcinoma models (PI, Duda)  
Merck Investigator Studies Program (MISP) / Preclinical Concept  
PI (\$536,444)  
The goal of this project is to establish the mechanism of benefit of the combination of the anti-HCC drug lenvatinib with anti-PD1 therapy using preclinical models.
- 2021–2026 A study of dual VEGF/PD-L1 blockade and liver SBRT in locally advanced, unresectable HCC (MPI, Wo/Duda/Kaseb/Koay)  
NCI / 1R01CA268605-01  
MPI (\$2,264,613)  
The goal of the proposed research is to demonstrate the activity and investigate the mechanism of action of dual VEGF/PD-L1 blockade with radiotherapy in patients with localized, unresectable HCC.
- 2022–2023 Leveraging multimodal therapy to achieve durable responses in liver cancer (PI, Duda)  
American Cancer Society Mission Boost Grant (Stage I)  
PI (\$200,000)  
The goal is to test whether high-dose radiotherapy will enhance HCC immunogenicity, and is effective when combined with anti-VEGF and anti-PD-L1 therapy in HCC models and in the majority of the advanced HCC patients.
- 2022–2024 Using anti-MET therapy combined with chemotherapies to eradicate occult pancreatic ductal adenocarcinoma micro-metastases (PI, Duda)  
DFCI-NIBR Drug Discovery & Translational Research Program / Grant  
PI (\$804,674)  
The goal of this project is to test whether the use of an anti-MET drug can disaggregate these cell clusters and make them more sensitive to standard chemotherapy and/or emerging immunotherapy to eradicate occult disease in patient-derived xenograft (PDX) models of liver and lung micro-metastasis in mice.
- 2022–2024 Leveraging experimental radiotherapy and checkpoint inhibitors to safely enhance B7-H3-specific CAR T cell-based immunotherapy efficacy in metastatic TNBC (MPI, Ferrone/Duda)  
DOD BCRP Breakthrough Level 2  
Partnering PI (\$750,000, subcontract)  
The goal of the proposed research is to demonstrate increased efficacy of CAR-T cells using radiotherapy and anti-PD-1 therapy in metastatic triple negative breast cancer.

### **Training Grants and Mentored Trainee Grants**

- 2006–2007 *Role of VEGFR1 in cancer metastasis* (PI, Michelle Dawson, PhD)  
Ford Foundation Diversity Research Fellowship  
Mentor  
The aim of this grant was to dissect the role of VEGFR1 in myeloid cells during spontaneous metastasis in mouse models.

- 2006–2007 *Role of primary tumor stroma in metastasis* (PI, Annique Pieters, MD, PhD)  
 Department of Defense Pre-doctoral Award  
 Co-Mentor  
 The aim of this grant was to dissect the role of carcinoma-associated fibroblasts from the primary tumor in spontaneous metastasis in mouse models.
- 2008–2010 *Mechanisms mediating cancer metastasis to the lungs* (PI, Sachie Hiratsuka, MD, PhD)  
 Scholarship Fund to Study Abroad Fellowship, Shiseikai, Japan  
 Co-Mentor  
 The aim of this grant was to dissect the role of vascular permeability in spontaneous metastasis in mouse models.
- 2014–2015 *Role of VEGF blockade in HCC* (PI, Tai Hato, MD, PhD)  
 Astellas Research Fellowship, Japan  
 Mentor  
 The aim of this grant was to dissect the mechanisms of response and resistance to VEGFR2 inhibition in hepatocellular carcinoma models.
- 2015–2017 *New combined therapy approaches for advanced prostate cancer* (PI, Daniel H. Schanne, MD)  
 Humboldt Foundation Feodor Lynen Research Fellowship, Germany  
 Mentor  
 The aim of this grant was to test the combination of CXCR4 with radiotherapy to treat bone metastasis in mouse models.
- 2016–2017 *Project title: Combination therapy using regorafenib and immunotherapy for HCC* (PI, Kohei Shigeta, MD, PhD)  
 Uehara Foundation Research Fellowship, Japan  
 Mentor  
 The aim of this grant was to dissect the mechanisms of response and resistance to regorafenib and PD1 blockade in hepatocellular carcinoma models.
- 2018–2019 *Role of PIGF/Nrp1 pathway in intrahepatic cholangiocarcinoma cell survival, tumor-associated fibrosis and abnormal vasculature* (PI, Shuichi Aoki, MD, PhD)  
 Cholangiocarcinoma Foundation 2018 Tommy J. West Memorial Research Fellowship  
 Mentor  
 The aim of this grant was to dissect the role of PIGF in cholangiocarcinoma progression and treatment resistance in mouse models.
- 2018–2021 *Immunotherapy combinations for intrahepatic cholangiocarcinoma* (PI, Jiang Chen, MD, PhD)  
 China Scholarship Council Project Postdoctoral Fellowship  
 Mentor  
 The aim of this grant is to test the mechanism and efficacy of the combination of chemotherapy with immunotherapy in cholangiocarcinoma mouse models.
- 2019–2021 *New therapy approaches to hepatocellular carcinoma* (PI, Lingling Zhu, MD)  
 China Scholarship Council Project Predoctoral Scholarship  
 Mentor  
 The aim of this grant was to test the mechanism and efficacy of the combination of radiotherapy with immunotherapy in HCC mouse models.
- 2019–2021 *Combination therapy using an immunomodulator (NLPR3 agonist) with immune checkpoint blockade for liver cancers* (PI, Zhangya Pu, MD)  
 China Scholarship Council Project Predoctoral Scholarship  
 Mentor  
 The aim of this grant is to test the mechanism and efficacy of the combination of an NPLR3 agonist with anti-VEGF and immune therapy in HCC mouse models.

- 2019–2021 *Combination therapy using a new oncolytic virus (VSV) with immune checkpoint blockade for liver cancers* (PI, Zhiping Ruan, MD, PhD)  
China Scholarship Council Project Fellowship  
Mentor  
The aim of this grant is to test the mechanism and efficacy of the combination of VSV therapy with immunotherapy in HCC mouse models.
- 2019–2021 *Combination therapy using an immunomodulator (STING agonist) with immune checkpoint blockade for liver cancers* (PI, Zelong Liu, MD, PhD)  
China Scholarship Council Project Fellowship  
Mentor  
The aim of this grant is to test the mechanism and efficacy of the combination of an STING agonist with anti-VEGF and immune therapy in HCC mouse models.
- 2019–2021 *Role of HGF pathway in radiation-induced liver damage* (PI, Franziska Hauth, MD)  
German Cancer Aid DAAD Fellowship  
Mentor  
The aim of this grant is to test circulating HGF as a biomarker of susceptibility to radiotherapy-induced liver damage in humans and in mouse models.
- 2019–2021 *Combination therapy using a new oncolytic virus (VSV) with immune checkpoint blockade for liver cancers* (PI, Zhiping Ruan, MD, PhD)  
China Scholarship Council Project Fellowship  
Mentor  
The aim of this grant was to test the mechanism and efficacy of the combination of VSV therapy with immunotherapy in HCC mouse models.
- 2020–2021 *Tomographic fluorescence lifetime multiplexing to quantify receptor expression* (PI, Rahul Pal, PhD)  
Jeane B. Kempner Scholarship  
Research mentor  
The goal of this work is to establish multiplexed imaging of PD-1 and VEGFR2 receptors during anti-angiogenic therapy in HCC models.
- 2021–2023 *Novel treatments for liver cancer* (PI, Satoru Morita, MD, PhD)  
Japan Society for the Promotion of Science Fellowship, Japan  
Mentor  
The aim of this grant was to test the mechanism and efficacy of the combination of systemic therapies with immunotherapy in HCC mouse models.

### **Unfunded Current Projects**

- 2019– Phase II Development of Novel Targeted Therapy for Hepatocellular Carcinoma – 2R44CA224642-02 (in preparation for resubmission)  
Site PI  
The goal of this Phase II SBIR application is to identify one liver tissue-targeting HDAC inhibitors (HDACi) and a backup candidate suitable for clinical development as new class of anti-HCC agents, alone or in combination with radiotherapy or systemic immunotherapy drugs.

### **Report of Local Teaching and Training**

#### **Teaching of Students in Courses:**

- 2002–2021 *Methods in Biomedical Engineering and Immunology* (annual)      Massachusetts General Hospital, HMS

	10-30 postdoctoral fellows, graduate students and technologists	3 hours of contact time with learners, 10 hours of preparation (Course Director and Faculty)
2005–2021	<i>Tumor Pathophysiology and Transport Phenomena</i> HST 525J Course (biennial)  30 graduate students and postdoctoral fellows	HMS / Massachusetts Institute of Technology (MIT) HST Program  2 hours contact time with learners; 3 hours of preparation (Faculty)
2011	<i>Tumor Angiogenesis as a Therapeutic Target: Current Progress and Future Directions</i>  Workshop at the 2011 Biorbis World Anti-Angiogenesis Summit, Boston, MA 8 MDs and PhDs	Hansonwade Life Sciences  3 hours of contact time with learners (Workshop Leader)
2011	<i>MGH - Chinese Oncologist Visiting Program</i> HMS Course, Boston, MA (annual)  12-15 leading Chinese surgeons / oncologists	Massachusetts General Hospital, HMS  1-2 hours of contact time with learners (Faculty)
2018–2021	<i>Mayo Clinic Pancreatic and Hepato-Biliary Cancer Symposium</i> (annual)  100 surgeons / oncologists	<i>Mayo Clinic</i> , Phoenix, AZ  1-2 hours of contact time with learners; 10 hours of preparation (Course Director and Faculty)

**Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs):**

2001–2019	Project advisor for undergraduate students in HST 525J Course on Tumor Pathophysiology / HMS-MIT (27 students since 2001)	Mentorship for 1-2 days
-----------	---	-------------------------

**Research Supervisory and Training Responsibilities:**

2002–2008	Co-mentor of graduate research student Josh Tam (MIT) / Steele Labs	Twice weekly mentorship for 6 years
2002–2008	Co-mentor of graduate research student Patrick Au/ (MIT)(AHA Award) / Steele Labs	Twice weekly mentorship for 6 years
2003–2005	Co-supervision of postdoctoral research fellow Mitsutomo Kohno (Keio University, Japan) / Steele Labs	Twice weekly mentorship for 2.5 years
2004	Supervision of summer research student Swaroop Vedula (HSPH) / Steele Labs	Daily mentorship for 1 month

2004	Supervision of summer research student Abraham Wei (HMS) / Steele Labs	Daily mentorship for 3 weeks
2004	Supervision of summer research student Margaret J. Kim (MIT) / Steele Labs	Daily mentorship for 3 weeks
2005–2008	Supervision of postdoctoral research fellow Michelle Dawson (Johns Hopkins University) (Ford Foundation Grant)/ Steele Labs	Daily mentorship for 3.5 years

*Michelle Dawson, PhD, Assistant Professor of Molecular Pharmacology, Physiology, and Biotechnology at Brown University, Providence, RI. She received a Ford Foundation Postdoctoral Minority Fellowship and published 4 original reports under the mentorship of Dr. Duda (1 in Nature).*

2005	Supervision of summer research student Nooshin Hosseini (Wellesley College/MIT) / Steele Labs	Daily mentorship for 4 weeks
2006– 2010	Co-supervision of postdoctoral research fellow Anniqve Pieters Duyverman (Univ. of Utrecht, The Netherlands)/ Steele Labs	Daily mentorship for 4.5 years

*Anniqve Duyverman, MD, PhD, received a Predoctoral Fellowship from the US Department of Defense and Published 7 original reports (3 Nature Protocols; 1 in PNAS; Journal of Clinical Oncology; Hepatology; Scientific Reports) under the mentorship of Dr. Duda. She is currently a staff surgeon, University of Utrecht, The Netherlands.*

2007	Supervision of summer research student Rehan Quadri (University of Maryland)/Steele Labs	Daily mentorship for 2 weeks
2007	Supervision of summer research student Roberto Velazquez (MIT)/Steele Labs	Daily mentorship for 6 months
2007	Supervision of summer research student Ernst Steller (University of Utrecht, The Netherlands)/Steele Labs	Daily mentorship for 2 months
2007– 2010	Co-supervision of postdoctoral research fellow Sachie Hiratsuka (Tokyo University, Japan)/Steele Laboratories	Daily mentorship for 3 years

*Sachie Hiratsuka, MD, PhD, received a Research Fellowship from Scholarship Fund to Study Abroad, Shiseikai, Japan and Published 2 original reports, both in the PNAS under the mentorship of Dr. Duda. She is currently a Professor, Sinsyu University School of Medicine, Japan.*

2008–	Co-supervision of postdoctoral research fellow Yuhui Huang (Vanderbilt University)/Steele Lab	Twice weekly mentorship since October 2008
2009	Supervision of research student Lotte Hiddingh (University of Utrecht, The Netherlands)/Steele Labs	Daily mentorship for 6 months
2009– 2011	Co-supervision of postdoctoral research fellow Rekha Samuel (India) (Indian Government Grant)/Steele Labs	Twice weekly mentorship for 2 years

*Rekha Samuel, MD, received a Scholarship from the Indian Government and published 4 original reports (Cancer Research, PNAS, Hepatology; Nature Protocols) under the co-mentorship of Dr. Duda. She is now a Professor / Scientist Centre for Stem Cell Research, Christian Medical College, Bagayam, Vellore, Tamil Nadu, India.*

2009– 2012	Co-mentor of graduate research student Shom Goel (University of Sydney, Australia) / Steele Laboratories	Twice weekly mentorship since July 2009
2009– 2012	Co-supervision of clinical research fellow Matija Snuderl (MGH Pathology) / Steele Labs	Twice weekly mentorship since January 2009
2010	Supervision of student Pedro Valencia (MIT) / Steele Labs	Daily mentorship for 3 months
2010– 2013	Supervision of postdoctoral research fellow Yunching Chen (University of North Carolina)/Steele Labs	Daily mentorship since June 2010

*Yunching Chen, PhD, published 6 original reports (2 Hepatology, PNAS; Nature Protocols; Scientific Reports; Theranostics) under the mentorship of Dr. Duda. Currently, she is a Professor / Institute of Biomedical Engineering at National Tsing Hua University, Taiwan.*

2010– 2013	Co-supervision of clinical research fellow Christine Lu (MGH)/Steele Labs	Twice weekly mentorship since September 2010
2012– 2013	Supervision of postdoctoral research fellow Cristina Karp (University of Cincinnati)/Steele Labs	Daily mentorship since November 2012
2012– 2014	Supervision of postdoctoral research fellow Hiroki Ochiai (Keio University, Japan)/Steele Labs	Daily mentorship since June 2012
2012– 2018	Supervision of MSc and PhD graduate research student Rakesh Ramjiawan (VU University Amsterdam, The Netherlands)/Steele Labs	Daily mentorship for 6 years since January 2012
2013– 2017	Supervision of postdoc Daniel Schanne (Freiburg University, Germany) Humboldt Fellow/Steele Labs	Daily mentorship since September 2013
2013– 2016	Supervision of postdoctoral research fellow Tai Hato (Keio University, Japan)/Steele Labs	Daily mentorship since September 2013

*Tai Hato, MD, PhD, received a Postdoctoral Fellowship from Astellas Foundation for Research on Metabolic Disorders, Japan, and published 9 articles (3 in Hepatology, 2 in Clinical Cancer Research, 1 in Gut, Red Journal, Scientific Reports and Immunotherapy) under the mentorship of Dr. Duda. He is currently a staff surgeon and director of translational research in the Dept. of General Thoracic Surgery, Saitama Medical Center, Saitama Medical University, Japan.*

2013– 2014	Supervision of undergraduate research student Toshiya Miyauchi (Tohoku University, Japan)/Steele Labs	Daily mentorship since November 2013
2014	Supervision of postdoctoral research fellow Yoshinori Hoshino (Keio University, Japan)/Steele Labs	Daily mentorship from Feb to Aug 2014
2014– 2016	Supervision of postdoctoral fellow Sen Li (Luzhou College) (China Science Council Grant)/Steele Labs	Daily mentorship from April 2014
2014– 2015	Supervision of undergraduate research student Takuya Suematsu (Tohoku Univ., Japan)/Steele Labs	Daily mentorship since November 2014
2014– 2017	Supervision of postdoctoral fellow Shuji Kitahara (Tokyo Women's Med Univ, Japan)/Steele Labs	Daily mentorship from July 2014

*Shuji Kitahara, DDS, PhD, published 5 original reports (2 in Hepatology, 1 in Gut, Scientific Reports and Cancers) under the mentorship of Dr. Duda. He is an Associate Professor of Anatomy, Tokyo Women Medical University, Japan.*

2014– 2015	Supervision of undergraduate research student Sebastian Klein (University of Munster, Germany) (Alex Lemonade Stand Grant)/Steele Labs	Daily mentorship for 10 months from November 2014
2014– 2017	Supervision of PhD graduate research student Nisha Gupta (VU Amsterdam, The Netherlands)/Steele Labs	Daily mentorship for 3 years since November 2014
2015	Supervision of undergraduate research student Matthew Boulanger (University of Rochester, NY)/Steele Labs	Daily mentorship for 3 months (June-Aug 2015)
2015	Supervision of MSc graduate student Monique de Beijer (VU, The Netherlands)/Steele Labs	Daily mentorship for 6 months since January 2015
2015	Supervision of undergraduate research student Paulo Moreira (University of Piauí, Brazil) Brazilian Scientific Mobility Program/Steele Labs	Daily mentorship for 3 months (June-Aug 2015)
2015– 2016	Supervision of undergraduate research student Glenn Geidel (University of Munster, Germany) (René Touraine Foundation Award)/Steele Labs	Daily mentorship for 12 months from October 2015



2016– 2018	Supervision of postdoctoral research fellow Kohei Shigeta (Keio University, Japan)/Steele Labs <i>Kohei Shigeta, MD, PhD, received a Fellowship from the Uehara Foundation and published 4 original reports (Hepatology, Clinical Cancer Research, Nature Biotechnology, Gut) under the mentorship of Dr. Duda. He is an Assistant Professor of Surgery, Keio University, Tokyo, Japan.</i>	Daily mentorship since April 2016
2016– 2019	Supervision of postdoctoral research fellow Shuichi Aoki (Tohoku University, Japan)/Steele Labs <i>Shuichi Aoki, MD, PhD, received a research grant from Tohoku University and a Fellowship from the Cholangiocarcinoma Foundation and published 4 articles (2 in Hepatology and 1 in Gut and Nature Biotechnology) under the mentorship of Dr. Duda. He is currently a staff surgeon, Tohoku University, Sendai, Japan.</i>	Daily mentorship since April 2016
2016	Supervision of undergraduate research student Halil Ibrahim Corbali (Fatih University, Turkey)	Weekly mentorship for 3 months (June-Aug 2016)
2016– 2017	Postdoctoral research fellow Emilie Mamessier (University of Aix-Marseille, France)/Steele Labs	Daily mentorship Nov 2016-Oct 2017
2016– 2017	Supervision of undergraduate research student Kevin Koch (University of Munster, Germany) (Boehringer Ingelheim Fonds Foundation for Basic Research in Medicine)/Steele Labs	Daily mentorship for 12 months from Aug 2016-July 2017
2017	Supervision of undergraduate research student Sonia Radu (Boston College)	Weekly mentorship for 2 months (June-Aug 2017)
2017– 2018	Supervision of postdoctoral research fellow Mi Na Kim (CHA University, Korea)/Steele Labs	Daily mentorship from July 1, 2017-May 31, 2018
2017	Supervision of undergraduate research student Max Traeger (University of Munster, Germany) (Boehringer Ingelheim Fonds Foundation for Basic Research in Medicine)/Steele Labs	Daily mentorship for 2 months from Aug-Oct 2017
2017–	Supervision of postdoctoral research fellow Aya Matsui (Tokyo Women University, Japan)/Steele Labs	Daily mentorship since April, 2017
2018– 2021	Supervision of postdoctoral research fellow Hiroto Kikuchi (Keio University, Japan)/Steele Labs <i>Hiroto Kikuchi, MD, PhD, published 5 articles (Hepatology, SGO, JITC, Gut and Nature) and has 2 manuscripts in preparation under the mentorship of Dr. Duda. He is currently a staff surgeon, Keio University, Tokyo, Japan.</i>	Daily mentorship April 2018-March 2021
2018– 2021	Supervision of postdoctoral research fellow Koetsu Inoue (Tohoku University, Japan)/Steele Labs	Daily mentorship since May 2018-February 2021
2018– 2019	Supervision of undergraduate research student Mie Yamanaka (Tohoku University, Japan)/Steele Labs	Daily mentorship since October 2018
2018– 2019	Supervision of undergraduate research student Masako Miyamoto (Tohoku Univ., Japan)/Steele Labs	Daily mentorship since October 2018
2018–	Supervision of postdoctoral research fellow Jiang Chen (Zhejiang University, China)/Steele Labs	Daily mentorship since Oct 2018
2018– 2019	Supervision of research fellow Yoon-Sun Choi (Inje University Busan, Korea)/Steele Labs	Daily mentorship Oct 2018-Sept 2019
2019– 2021	Supervision of undergraduate research student Daniel Staiculescu (U Mass)/Steele Labs	Daily mentorship Mar 2019-March 2021
2019	Supervision of undergraduate research student Shiho Hirose (Univ. of Tokyo, Japan)/Steele Labs	Daily mentorship May-Aug 2019
2019– 2020	Supervision of postdoctoral research fellow Kazumichi Kawakubo (Hokkaido University, Japan)/Steele Labs	Daily mentorship June 2019-Apr 2020

2019– 2020	Supervision of undergraduate research student Masaaki Iwasaki (Tohoku University, Japan)/Steele Labs	Daily mentorship Sept 2019-Jan 2020
2019– 2020	Supervision of undergraduate research student Kanshiro Suzuki (Tohoku Univ., Japan)/Steele Labs	Daily mentorship Sept 2019-Jan 2020
2019– 2020	Supervision of undergraduate research student Tyge Schmidt (Univ. of Munster, Germany)/Steele Labs	Daily mentorship from Sept 2019-Apr 2020
2019– 2021	Supervision of graduate research student Lingling Zhu (University of Sichuan, China)/Steele Labs	Daily mentorship from Nov 2019-Jan 2021
2019– 2021	Supervision of postdoctoral research fellow Zhiping Ruan (X'ian University, China)/Steele Labs	Daily mentorship since Oct 2019
2019– 2021	Supervision of graduate research student Zhangya Pu (Central South University, China)/Steele Labs	Daily mentorship from Dec 2019-
2019– 2022	Supervision of postdoctoral research fellow Ze-Long Liu (Sun-Yat Sen University, China)/Steele Labs	Daily mentorship from Dec 2019-
2021–	Supervision of postdoctoral research fellow Satoru Morita (Keio University, Japan)/Steele Labs	Daily mentorship since April 2021
2021–	Supervision of postdoctoral research fellow Hajime Taniguchi (Tohoku University, Japan)/Steele Labs	Daily mentorship since April 2021
2021–	Supervision of PhD student Ling-yu Tian (Peking University, China)/Steele Labs	Daily mentorship since July 2021

**Formally Mentored Harvard Medical, Dental and Graduate Students:**

2015      PhD Qualifying Exam Committee Member for Ph.D. Candidate Morad Golnaz, in the Program in Biological Sciences in Dental Medicine, Harvard University, class of 2020. Successfully defended thesis: “*The role of breast cancer-derived extracellular vesicles in brain metastasis*” in 2020.

**Other Mentored Trainees and Faculty:**

2012–  
2019      Janet E. Murphy, MD, MPH / Instructor of Medicine, MGH, HMS.  
Career stage: junior faculty. Mentoring role: research advisor. Accomplishments: received an K12 grant from the NCI (Proton Beam Federal Share Program) and published 1 article as first author in *JAMA Oncology* (2019).

2017–      Clemens Grassberger, PhD / Assistant Professor of Radiation Oncology, MGH, HMS.  
Career stage: junior faculty. Mentoring role: research advisor. Accomplishments: received an R21 grant from the NIH (one R01 grant pending), was promoted to Assistant Professor at MGH and HMS in 2019 and Assistant Program Director (Radiation Biology) in 2021, and published 3 articles with Dr. Duda as co-mentor (2 in *Int J Radiat Oncol Biol Phys* and 1 in *npj Precision Oncology*).

2019–      Hanny Al-Samkari, MD / Instructor of Medicine, MGH, HMS.  
Career stage: junior faculty. Mentoring role: research advisor. Accomplishments: received a grant from the CureHHT foundation (one K23 grant pending) for his correlative studies of VEGF blockade in hereditary hemorrhagic telangiectasia (HHT) patients, and was promoted to Associate Director, Hereditary Hemorrhagic Telangiectasia Center at MGH in 2020.

- 2020– Anwaar Saeed, MD / Assistant Professor of Oncology, University of Kansas Medical Center. Career stage: junior faculty. Mentoring role: research advisor. Accomplishments: successfully designed a clinical trial, approved by the SWOG consortium; SWOG grant pending.
- 2020– Mehmet Akce, MD / Assistant Professor of Oncology, Emory University. Career stage: junior faculty. Mentoring role: research advisor. Accomplishments: K08 grant pending.
- 2020– Ali Ajdari, PhD / Instructor of Radiation Oncology, MGH, HMS. Career stage: junior faculty. Mentoring role: research advisor. Accomplishments: K99/R00 grant pending and has reported 1 biomarker study as first author in *JCO Clinical Cancer Informatics* (2021).

**Formal Teaching of Peers (e.g., CME and other continuing education courses):**

- No presentations below were sponsored by 3<sup>rd</sup> parties/outside entities
- Those presentations below sponsored by outside entities are so noted and the sponsor(s) is (are) identified.

- |      |   |                |
|------|---|----------------|
| 2009 | “Pursuing potential biomarkers of response and resistance to antiangiogenic therapy: Which ones and why?” / Invited seminar speaker<br>The weekly DFCI and BWH Neuro-Oncology Fellowship Conference | 1 talk, Boston |
| 2012 | “Correlative Studies in Clinical Trials of Antiangiogenics” / Faculty<br>The weekly MGH/DFCI/BWH Neuro-oncology Fellowship Conference, Pappas Center for Neuro-Oncology at MGH                      | 1 talk, Boston |
| 2012 | "Angiogenesis and antiangiogenesis in tumors of the central nervous system"/Invited speaker<br>The monthly MGH Pathology InterLaboratory Conference   | 1 talk, Boston |
| 2013 | “Targeting inflammatory pathways as a sensitization approach” / Invited seminar speaker<br>MGH GI Group Research Meeting  | 1 talk, Boston |
| 2014 | “Correlative Studies in Clinical Trials of Antiangiogenics” / Faculty<br>The weekly MGH/DFCI/BWH Neuro-oncology Fellowship Conference, Pappas Center for Neuro-Oncology at MGH                      | 1 talk, Boston |
| 2015 | “Role of correlative studies in trials of antiangiogenics in brain tumors: What have we learned?” / Faculty<br>The weekly DFCI/BWH Neuro-oncology Fellowship Conference, DFCI Neuro-Oncology Dept.  | 1 talk, Boston |
| 2016 | “The role of circulating biomarkers in improving upper GI cancer treatment” / Speaker<br>MGH GI Multidisciplinary Research Meeting, MGH Cancer Center   | 1 talk, Boston |

### **Local Invited Presentations:**

- No presentations below were sponsored by 3<sup>rd</sup> parties/outside entities*  
 *Those presentations below sponsored by outside entities are so noted and the sponsor(s) is (are) identified.*

- 2009            “A phase II study of blood circulating cells and plasma angiogenic proteins as biomarkers of anti-VEGF therapy with bevacizumab in sarcoma patients” / 2008 Ira J. Spiro Translational Research Award Presentation  
The 2nd Research Retreat of the Department of Radiation Oncology at MGH
- 2009            “Potential circulating biomarkers for antiangiogenic therapy in HCC” / Invited speaker  
The DF/HCC Hepatocellular Research Day
- 2009            “On and off target with antiangiogenic therapies” / Grand Rounds in Oncology  
Department of Hematology/Oncology DF/HCC, Harvard Medical School
- 2010            "On and off target with antiangiogenic therapies" / Invited seminar speaker  
Boston Romanian Biomedical Scientists Group Seminar Series, HMS
- 2011            “Work-In-Progress Meeting” / Invited seminar speaker  
DF/HCC Angiogenesis Invasion and Metastasis (AIM): Children's Hospital Vascular Biology Program, Boston, MA
- 2011            “A study of SDF1/CXCR4 as a potential mechanism of distant progression in pancreatic cancer after neoadjuvant chemoradiation” / 2010 Ira J. Spiro Translational Research Award Presentation and Session Moderator  
The 4th Research Retreat of the Department of Radiation Oncology at MGH
- 2013            “Correlative Studies of Circulating Biomarkers in Clinical Trials” / Invited seminar speaker  
MGH QTIM Neuro-Oncology Program
- 2015            “Prevention of development of liver tumors in a pre-malignant field” / Speaker  
DF/HCC Liver Cancer Grant Incubator, DFCI
- 2017            “Cancer biology” / Invited speaker  
MIT NIH P41 Laser Biomedical Research Center Site Visit, MIT
- 2017            “Using biomarkers to understand the role of the tumor microenvironment in treatment resistance” / Speaker  
MGH Radiation Oncology Immuno-Oncology Working Group Meeting, MGH Cancer Center
- 2019            “Rapidly evolving strategies for liver cancer treatment” / Seminar speaker  
Vascular Biology Seminar, Children's Hospital & Harvard Medical School

### **Report of Regional, National and International Invited Teaching and Presentations**

- No presentations below were sponsored by 3<sup>rd</sup> parties/outside entities*  
 *Those presentations below sponsored by outside entities are so noted and the sponsor(s) is (are) identified.*

### **Regional**

- 2005 “Marker specificity, cell viability, and origin of circulating endothelial cells (CECs): Implications for the use of CECs as biomarker for antiangiogenic therapy” / Speaker (abstract)  
The AACR Special Conference Anti-Angiogenesis and Drug Delivery to Tumors: Bench to Bedside and Back, Waltham, MA
- 2006 “Contribution of bone marrow-derived endothelial cells to tumor vessels and potential use of circulating endothelial cells (CECs) as a biomarker of anti-VEGF therapy” / Invited speaker  
Strategic Research Institute 4th Angiogenesis Drug Discovery and Development, Boston, MA
- 2007 “The Role of Circulating Endothelial and Progenitor Cells in Cancer” / Keynote talk  
The 5th IBC Life Sciences Meeting on Anti-Angiogenesis, Boston, MA
- 2010 “Pursuing biomarkers of response and resistance to antiangiogenic therapy” / Invited speaker  
Center of Cancer Systems Biology Seminar Series, TUFTS University, Boston, MA
- 2011 “Translational studies for angiogenesis biomarkers” / Invited speaker  
The 9th International M. Judah Folkman Conference Antiangiogenesis: New Frontiers in Therapeutic Development, Cambridge, MA
- 2011 “VEGF: Natural target” / Invited speaker  
13th Annual Boston Angiogenesis Meeting (BAM 2011), MIT, Cambridge, MA
- 2014 “Potential Circulating Biomarkers of Response to Targeted Therapy” / Invited speaker  
Annual “Circulating Cancer Biomarkers”, Boston, MA (HansonWade)
- 2015 “Circulating biomarkers to evaluate cancer response and resistance to targeted therapies” / Invited speaker  
Cambridge Biomedical Seminar Series, Cambridge, MA
- 2015 “Role of anti-angiogenesis in the immunotherapy era” / Invited speaker  
17th Annual Boston Angiogenesis Meeting (BAM 2015), Schepens Eye Institute, Boston, MA
- 2016 “Antiangiogenesis for cancer therapy” / Plenary invited talk  
World Congress of Interventional Oncology, Boston
- 2016 “Facilitating immune checkpoint blockade in HCC” / Invited speaker and Chair of Session: GI Cancer Therapy and Chemotherapy-PD-1 Combinations  
Cancer Immunotherapy and Combinations, 15th annual World Preclinical Congress, Boston
- 2020 “Rapidly evolving strategies for liver cancer treatment” / Seminar speaker  
Surface Oncology Seminar, Cambridge, MA (Surface Oncology)
- 2021 “Multiple Obstacles Need to be Overcome to Prevent Resistance to CAR T Cell Therapy of Solid Tumors” / Invited speaker and Leader of Panel: Combinatorial Approaches Using Radiotherapy and Immunotherapy  
Cambridge Healthtech Institute’s 11th Annual Antibodies for Cancer Therapy/Driving Breakthrough Therapies, Cambridge, MA (virtual)

## National

- 1999 “Interleukin 12 gene therapy for pancreatic cancer” / Speaker (abstract)  
The 42nd Symposium of the Japanese Microcirculation Society, Yokohama, Japan
- 1999 “In vivo analysis of IL-12 antiangiogenic gene therapy for pancreatic cancer” / Invited speaker  
The 24th Annual Meeting of Japanese College of Surgeons, Kobe, Japan
- 2001 “Effects of SMAD4 gene therapy in pancreatic adenocarcinoma” / Speaker (abstract)

- The 92nd Meeting of the American Association for Cancer Research, New Orleans, LA  
(Ito-En-AACR Travel award)
- 2004 “Paracrine regulation of angiogenesis and adipogenesis: A potential link with cancer” /  
Speaker (abstract)
- 2005 The 95th Meeting of the American Association for Cancer Research, Orlando, FL  
“Evaluation of circulating precursor cells as surrogate markers for antiangiogenic  
therapies of cancer” / Speaker (abstract)
- 2006 The 3rd Meeting of the International Society for Stem Cell Research, San Francisco, CA  
“Antivascular agents: Anti-VEGF therapy for cancer” / Speaker (Faculty)
- 2006 The 2nd ASTRO Annual Translational Research in Radiation Oncology: Physics and  
Biology Meeting, Boston (ASTRO)
- 2006 “Measurement of CECs as a biomarker for antiangiogenic therapy: Surface marker  
specificity, cell viability, and origin of circulating endothelial cells” / Speaker (abstract)
- 2006 The 97th Meeting of the American Association for Cancer Research, Washington, DC  
“Evidence for bone marrow-derived endothelial cells incorporation into perfused blood  
vessels in tumors” / Speaker (abstract)
- 2007 The 97th Meeting of the American Association for Cancer Research, Washington, DC  
“Phenotypic characterization of circulating cells” / Invited speaker
- 2007 The 1st Avastin Diagnostic Summit, Washington, DC (NCI/Genentech)
- 2007 “Antiangiogenesis for solid tumors: bench to bedside and back” / Invited speaker  
Takeda Global Experts Meeting, Chicago, IL (Takeda)
- 2008 “Circulating endothelial cells and their potential role in tumor progression and treatment”  
/ Invited speaker
- 2008 The RTOG Translational Research Program, Stem Cell symposium, San Diego, CA  
(RTOG)
- 2008 “Evaluation of changes in blood angiogenic markers as biological markers for treatment” /  
Invited speaker
- 2008 Brain Tumor Translational Research Program, RTOG Semi-Annual Meeting, San Diego,  
CA
- 2008 “The Role of Circulating Progenitor Cells in Solid Tumors” / Invited seminar  
Lerner Research Institute, Cleveland Clinic, Cleveland, OH (Cleveland Clinic)
- 2008 “Phenotypic and functional characterization of pro-angiogenic monocytes / Speaker  
(abstract)
- 2009 The 2008 Experimental Biology Meeting (FASEB), San Diego, CA  
“Antiangiogenic therapy for cancer patients: Mechanisms of action and potential  
predictive biomarkers or response and resistance” / Grand rounds  
Greenebaum Cancer Center, University of Maryland, Baltimore (Univ. of Maryland)
- 2009 “Pursuing potential biomarkers of response and resistance to antiangiogenic therapy:  
Which ones and why?” / Invited seminar  
Division of Oncology, Cancer Biology Research Seminar, Madison (Univ. of Wisconsin)
- 2009 “A “Vascular Normalization Index” as a mechanistic biomarker to predict survival after a  
single dose of cediranib in recurrent glioblastoma patients” / Plenary Talk
- 2009 The 100th Meeting of the AACR, Denver, CO (AACR)
- 2009 “Role of vascular normalization in brain tumors” / Invited speaker and discussant  
The 2009 Forbeck Forum “The Biology and Treatment of Primary Brain Tumors”, Hilton  
Head Island, SC (Forbeck Foundation)
- 2009 “Role of circulating progenitor cells in tissue repair and tissue engineering: Lessons from  
tumor studies” / Invited seminar  
Cardiovascular Research Center Seminar, Madison, WI
- 2009 “Role of circulating progenitor cells in tissue repair and tissue engineering: Lessons from  
tumor studies” / Invited seminar

- 2011 CT Division Educational Conference, Madison, WI (University of Wisconsin)  
 “Future Directions: Predictive Biomarkers of Response and Resistance to Anti-Angiogenic Therapy” / Invited speaker and discussant  
 Angiogenesis: Breakthroughs in Basic Science and Therapeutic Applications Symposium, The New York Academy of Sciences, New York, NY (Johnson & Johnson)
- 2012 “Biomarkers of Antiangiogenic Therapy” / Invited speaker and panelist  
 “Circulating Cancer Biomarkers: Practical Applications to Drive Drug Development and Personalized Medicine in the Clinic”, Washington, DC (HansonWade)
- 2013 “Clinical translation of mouse model data in cancer” / Invited speaker  
 American Society for Clinical Pharmacology and Therapeutics, Indianapolis, IN (ASPCT)
- 2014 “Does vascular normalization improve delivery of cancer therapeutics?”/ Speaker & panelist, Chair of Session: Biomarkers for Anti-angiogenic Cancer Treatment  
 “Targeting VEGF-mediated Tumor Angiogenesis in Cancer Therapy” Symposium, The New York Academy of Sciences, New York, NY (NYAS)
- 2014 “Determinants of HCC resistance to sorafenib treatment” / Invited seminar  
 Department of GI Oncology, MD Anderson Cancer Center, Houston, TX (University of Texas)
- 2015 “Biomarkers of response and resistance to anti-angiogenic therapy” / Invited speaker  
 The AACR Special Conference on Tumor Angiogenesis and Vascular Normalization, Orlando
- 2016 “Role of targeted therapies in hepatocellular carcinoma: Choosing the right combinations” / Invited Translational Research Conference  
 Johns Hopkins University Cancer Center, Baltimore, MD
- 2016 “Finding the Right Therapeutic Combinations: Lessons from Translational Studies in Clinical Trials and Preclinical Models” / Invited Seminar  
 Bristol Myers Squibb, San Francisco, CA (BMS)
- 2016 “Lessons from translational studies of targeted therapy and radiotherapy in clinical trials and preclinical models” / Invited seminar  
 Department of Radiation Oncology, Duke Univ. Medical Center, Durham, NC (Duke Univ.)
- 2016 “Preclinical sorafenib immune modulation and anti-tumor activity in combination with IO in HCC models” / Invited speaker  
 Bayer Cancer Immunotherapy Advisory Board Meeting, New York, NY (Bayer)
- 2017 “Angiogenesis and tumor microenvironment” / Invited speaker  
 2017 Society of Interventional Radiology Annual Scientific Meeting, Washington, DC (SIR)
- 2017 “Systemic therapy for liver cancer” / Grand Rounds in Oncology  
 Mayo Clinic, Scottsdale, AZ (Mayo Clinic)
- 2017 “Role of CXCR4 in Reprogramming the Tumor Microenvironment for Radiation or Immuno-therapy” / Invited Seminar  
 Bristol Myers Squibb, San Francisco, CA (BMS)
- 2018 “Reprogramming the HCC Microenvironment for Immunotherapy” / Invited seminar  
 Department of GI Oncology, MD Anderson Cancer Center, Houston, TX (University of Texas)
- 2018 “How to take advantage of the biology of cancer?” / Invited speaker  
 35th “Medical Surgical Gastroenterology: A Multidisciplinary Approach” Course, Avon, CO
- 2018 “How to take advantage of the biomarker for GI cancer treatment?” / Invited speaker  
 2018 Mayo Clinic Hepato-Pancreato-Biliary Cancers Symposium, Phoenix, AZ (Mayo Clinic)

- 2019 “State of the Science in HCC” / Faculty and Chair of Session – Systemic therapy advances in HCC  
2019 Mayo Clinic Hepato-Pancreato-Biliary (HPB) Cancers Symposium, Las Vegas, NV (Mayo Clinic)
- 2020 “Rapidly evolving strategies for the treatment of liver cancer” / Grand Rounds  
Fred Hutchinson Cancer Center/University of Washington, Seattle, WA (UW)
- 2021 “Reprogramming tumor microenvironment to enhance immunotherapy for HCC” / Invited seminar  
SPORE Program, MD Anderson Cancer Center, Houston, TX (University of Texas)
- 2021 “New insights into the rapidly evolving treatment paradigms for liver cancers” / Invited Visiting Professor seminar  
Seminar at University of Michigan. Host: Dr. M. Morgan, Associate Chair for Radiation and Cancer Biology, Lawrence-Krause Research Professor of Radiation Oncology (University of Michigan Medical School)

## International

- 1998 “Antiangiogenic gene therapy with IL-12 in pancreatic cancer” / Speaker (abstract)  
The 8th Meeting of the International Association of Pancreatology, Tokyo, Japan
- 2000 “Direct in vitro evidence and in vivo analysis of the anti-angiogenesis effects of Interleukin 12” / Speaker (abstract)  
The 2nd Roche International Symposium on Tumor Angiogenesis and Matrix, Tokyo, Japan
- 2004 “Effects of anti-VEGF therapy in cancer patients” / Invited special seminar  
Evidence-Based Medicine Symposium, Sendai, Japan (Chugai Pharmaceutical)
- 2004 “Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma” / Speaker (abstract)  
The 11th Meeting of the Intl Association of Pancreatology, Sendai, Japan (Travel Award)
- 2005 “Effects of bevacizumab in rectal cancer patients” / Invited speaker and Chair of Session: Cancer-Basic  
The 11th Annual Taishotoyama International Symposium, Shimoda, Japan (Taishotoyama)
- 2006 “Contribution of bone marrow-derived endothelial cells to tumor neovascularization and potential use of circulating endothelial cells as a biomarker” / Speaker (abstract)  
The 6th EuroConference on Angiogenesis, Mandelieu, France (European Union Scholarship)
- 2006 “Rational basis for combination of chemotherapy and antiangiogenic drugs” / Invited speaker  
The 3rd Intl Symposium on Angiogenesis and Cancer, Malaga, Spain (University of Malaga)
- 2007 “The role of circulating endothelial and progenitor cells in disease” / Plenary talk  
The 13th Annual Meeting of the International Society for Cell Therapy (ISCT), Sydney, Australia (ISCT)
- 2007 “Antiangiogenesis for solid tumors: bench to bedside and back” / Invited speaker and Chair of Session: Molecular Biology  
The 17th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO), Bucharest, Romania (IASGO)
- 2007 “Potential for integration of antiangiogenic therapy with chemoradiation in solid cancers” / Invited speaker



- The 2nd Langendorff Congress for Radiobiological Research, Germany (Univ. of Freiburg)
- 2008 “Deciphering tumor patho-physiology in preclinical models: Impact on the integration of new biological agents in cancer treatment” / Invited speaker and Chair of Session: Role of Tumor Microenvironment for Radiotherapy  
Connecting Diaspora with the Romanian Scientific Community, Bucharest (Romanian Govt)
- 2008 “The role of circulating precursor cells in adult neovascularization” / Invited speaker  
Ramon Areces Foundation’s 1st International Symposium on Angiogenesis and Cancer: From Basic Mechanisms to Therapeutic Applications, Malaga, Spain (University of Malaga)
- 2008 “Potential predictive factors for efficacy in anti-angiogenic therapy” / Invited speaker and Chair of Session: New Concepts – New Therapeutic Strategies  
The 4th International Symposium on Angiogenesis and Cancer, Spain (University of Malaga)
- 2009 “Functional imaging of tumor vasculature after antiangiogenic therapy” / Invited speaker  
The 3rd Langendorff Symposium, Freiburg, Germany (University of Freiburg)
- 2010 “Antiangiogenic therapy for cancer: from concept confirmation towards individualized treatment” / Invited speaker  
The 5th Cajal Symposium on Translational Research, Bucharest, Romania (Cajal Foundation)
- 2010 “Visualization of tumor vasculature after antiangiogenic therapy” / Invited speaker and Chair of Session: Potential advantages and pitfalls of anti-vascular and anti-angiogenic treatments  
The 29th European Society for Radiotherapy & Oncology (ESTRO) Annual Meeting, Barcelona, Spain (ESTRO)
- 2011 “Metastasis: Seed and soil hypothesis revisited” / Invited speaker  
Seminar at Keio University Medical School, Tokyo, Japan. Host: Dr. Makoto Suematsu, Dean of School of Medicine, Keio University
- 2011 “Antiangiogenic therapy and metastasis” / Invited speaker  
The 6th Cajal Symposium on Translational Research, Bucharest, Romania
- 2011 “Antiangiogenic therapy for cancer: How does it work and how does it fail?” / Invited speaker  
Seminar at Duke-National University of Singapore (NUS) Medical School. Host: Professor David M. Virshup, Director of the Cancer & Stem Cell Biology Program, NUS, Singapore
- 2011 “Metastasis: Seed and soil hypothesis revisited” / Invited speaker  
Seminar at Barts & the London, Queen Mary’s School of Medicine & Dentistry, London, UK
- 2012 “Antiangiogenic therapy for HCC” / Invited speaker  
The 7th Cajal Symposium on Translational Research, Bucharest, Romania (Cajal Foundation)
- 2012 “Tumor biology and metastasis” / Invited speaker  
The 7th International Symposium of Institute Network, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan (Tohoku University)
- 2012 “Targeted therapy of colorectal and liver cancer” / Invited speaker  
Seminar at Kitakami Hospital, Department of Surgery, Kitakami, Japan (Kitakami Hospital)
- 2012 “Antiangiogenesis in liver cancer” / Invited speaker  
Queen Mary Hospital, Li Ka Shing Faculty of Medicine, Hong Kong University, China
- 2012 “On and Off-target with Antiangiogenic Therapy for Cancer” / Invited speaker

- Area of Excellence Seminar at Centre for Cancer Research, Hong Kong University (Bayer)
- 2012 “Challenges in clinical research” / Invited speaker and panelist  
Connecting Diaspora with the Romanian Scientific Community Conference, Bucharest, Romania (Romanian Government)
- 2013 “Translational imaging in animal models” / Invited speaker  
International Workshop Translational imaging in gastroenterology and surgery, Craiova, Romania (University of Medicine Craiova)
- 2013 “Translational imaging in clinical trials” / Invited speaker  
International Workshop Translational imaging in gastroenterology and surgery, Craiova, Romania (University of Medicine Craiova)
- 2013 “New directions in advanced HCC therapy with targeted agents” / Invited speaker and Chair of Session: Cancer Genomics  
The 8th Cajal Symposium on Translational Research, Bucharest, Romania (Cajal Foundation)
- 2013 “Metastatic colonization: Evolving paradigms” / Invited speaker  
Seminar at the VU University Medical Center, Amsterdam, The Netherlands
- 2013 “The challenge of integrating molecularly targeted therapies against cancer stroma: Different degrees of treatment personalization” / Invited speaker and Chair of Session: Novel Diagnostic and Tools for Cancer Treatment  
The 23rd Annual IASGO World Congress, Bucharest, Romania (IASGO)
- 2013 “Combining radiation with targeted therapies: Why, how and when?” / Guest speaker  
The 5th Langendorff Symposium on Personalized Medicine, Germany (University of Freiburg)
- 2013 “Combining stroma-targeted therapies with radiation to prevent resistance” / Invited speaker  
New Cancer Targets Symposium, Integrative Radiation Oncology session, Heidelberg, Germany (National Center for Tumor Disease and German Cancer Research Center)
- 2014 “Antiangiogenic strategy for colorectal cancer” / Invited speaker  
Workshop on Colorectal Cancer, IASGO Educational Program, Pordenone, Italy (IASGO)
- 2014 “Targeted immunotherapy for rectal cancer: New perspectives” / Invited speaker  
Workshop on Colorectal Cancer, IASGO Educational Program, Pordenone, Italy (IASGO)
- 2014 “Impact of the inflammatory tumor microenvironment on radiation response of cancers” / Invited speaker  
The 33th European Society for Radiotherapy & Oncology (ESTRO) Annual Meeting, Vienna, Austria (ESTRO)
- 2014 “Determinants of HCC resistance to anti-VEGF therapy” / Invited speaker  
Host: Professor Markus Peck, UniMedWien Cancer Center, Austria (University of Vienna)
- 2014 “Role of tumor microenvironment in radiation response” / Invited speaker  
Host: Professor Michael Baumann, University of Dresden, Germany (University of Dresden)
- 2014 “Mechanism-based combination therapy approaches for intractable cancers” / Invited speaker  
The 9th Cajal Symposium on Translational Research, Bucharest, Romania (Cajal Foundation)
- 2014 “Mechanism-based targeting of tumor stroma in intractable cancers” / Invited speaker  
Invited Seminar, Keio University, Tokyo, Japan (Keio University)
- 2014 “Rationally exploiting antiangiogenesis for improving HCC therapy” / Invited speaker  
International Symposium on Vascular Biology, Sendai, Japan (Tohoku University)

- 2014 “Translational Studies in Clinical Trials of Targeted Therapies for Cancer” / Invited speaker  
Workshop on GI Cancer, IASGO Educational Program of the, Moscow, Russia (IASGO)
- 2014 “GI cancer therapy with antiangiogenics: Lessons from translational studies” / Invited speaker  
The 24th Annual World Congress of the IASGO, Vienna, Austria (IASGO)
- 2014 “Role of Multidisciplinary Translational Studies of Agents Targeting the Cancer Vasculature and the Immune System” / Invited speaker  
The 24th Annual World Congress of the IASGO, Vienna, Austria (IASGO)
- 2015 “Mechanisms of Treatment Evasion for Antiangiogenic Therapy” / Visiting Professor Seminar  
University of Freiburg, Germany (University of Freiburg)
- 2015 “Rationally Combining Antiangiogenic Therapy with Checkpoint Inhibitors in Hepatocellular Carcinoma” / Plenary Speaker (Short talk)  
Keystone Symposium on Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7), Banff, Canada
- 2015 “Antiangiogenic Therapy: Quo Vadis” / Visiting Professor Seminar  
University of Freiburg, Germany (University of Freiburg)
- 2015 “Translation of anticancer efficacy from non-clinical models to the clinic using biomarkers” / Keynote speaker  
The 14th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology, Wolfsberg Castle, Lake Konstanz, Switzerland (ESTRO)
- 2015 “Personalizing targeted therapies for cancer: Current progress” / Invited speaker  
The 10th Cajal Symposium on Translational Research, Bucharest, Romania (Cajal Foundation)
- 2015 “IASGO Postgraduate Study Center Plans” / Plenary speaker  
The 6th Congress of Kazakhstan Surgeons, Almaty, Kazakhstan (IASGO)
- 2015 “Systemic therapy for hepatocellular carcinoma: Challenges and promise” / Seminar speaker  
Seminar, Tohoku University Sendai, Japan. Host: Professor Michiaki Unno (Tohoku Univ.)
- 2015 “Biomarkers of cancer response and resistance to anti-angiogenic therapy” / Invited speaker  
Workshop on GI Cancer, IASGO Educational Program, Jikei University School of Medicine, Tokyo, Japan (IASGO)
- 2015 “Translation of anticancer efficacy from non-clinical models to the clinic using biomarkers” / Seminar speaker  
Radiation Oncology Colloquium Seminar. Hosts: Professors Peter Rodemann and Daniel Zips, University of Tübingen, Germany (University of Tuebingen)
- 2015 “Development of Systemic Therapies for Liver Cancer” / Invited speaker  
Workshop on Hepatobiliary Surgery, IASGO Educational Program, Haikou, China (IASGO)
- 2015 “Development of Novel GI Cancer Therapies” / Seminar speaker  
Institute of Biomedical Engineering, NTHU, Taiwan (Tsing Hua University)
- 2015 “Development of Novel Gastrointestinal Cancer Therapies” / Seminar speaker  
Academia Sinica, Taipei, Taiwan. Host: Dr. Han-Chung Wu (Academia Sinica)
- 2015 “Translation of Targeted Agents for GI Cancer Therapy” / State-of-the-Art Lecture and Chair of Session: Pancreatic Neoplasms  
The 25th Annual World Congress of the IASGO, Fuzhou, China (IASGO)
- 2015 “Translational Studies in Clinical Trials of Targeted Therapies for Cancer” / Invited speaker

- 2015 Workshop on GI Cancer, Educational Program of the IASGO, Moscow, Russia (IASGO)  
 “Angiogenesis and immunology” / Invited speaker  
 The 6th Langendorff Symposium in Radiation Oncology, Germany (University of Freiburg)
- 2015 “Biomarkers in pancreatic cancer and in hepatocellular cancer” / Invited speaker  
 The 6th Langendorff Symposium Imaging in Radiation Oncology, Germany (Univ. of Freiburg)
- 2015 “Lessons from translational studies in clinical trials and preclinical models” / Seminar speaker  
 Sunnybrook Research Institute, Toronto, Canada. Host: Dr. Robert Kerbel (Toronto University)
- 2015 “Lessons from translational studies in clinical trials and preclinical models” / Seminar speaker  
 University of Ulm, Germany (University of Ulm) Host: Dr. Doris Henne Bruns
- 2015 “Going beyond antiangiogenesis in brain tumors” / Keynote Lecture  
 Neurooncology Group Winterschool, Freiburg, Germany (University of Freiburg)
- 2016 “Pancreatic cancer: Determinants of metastasis”/ Invited speaker and Chair of Session: GI Cancer Therapy  
 The 11th Cajal Symposium on Translational Research, Bucharest, Romania (Cajal Foundation)
- 2016 “Hepatocellular carcinoma: Role of circulating biomarkers”/ Invited speaker  
 The 11th Cajal Symposium on Translational Research, Bucharest, Romania (Cajal Foundation)
- 2016 “Translational oncology: From increased understanding to better outcomes” / Invited speaker  
 Humanitas University, School of Medicine, Milan, Italy
- 2016 “Biomarkers for optimization of novel radiotherapy-drug combinations” / Invited faculty  
 ESTRO 35 Pre-Meeting Course, Turin, Italy (ESTRO)
- 2016 “Therapeutic Vascular Normalization” / Plenary speaker  
 5th Metronomics and Anti-Angiogenesis Meeting in Mumbai, India (Tata Medical Center)
- 2016 “Identifying new targets and biomarkers of cancer response through correlative clinical studies” / Invited speaker  
 71st Meeting of Japanese Society of Gastroenterological Surgery, Tokushima, Japan (JSGS)
- 2016 “Overcoming resistance to systemic therapies in liver cancer” / Invited seminar  
 University of Nagasaki, Japan. Host: Professor Susumu Eguchi (University of Nagasaki)
- 2016 “Role of translational studies in multidisciplinary trials of anti-cancer agents” / Invited seminar  
 University of Kyoto, Japan. Host: Professor Masazaku Toi
- 2016 “Exploiting biomarkers of cancer response and resistance” / Special Lecture  
 Workshop on GI Cancer, IASGO Educational Program, Tohoku University School of Medicine, Sendai, Japan (Tohoku University)
- 2016 “Role of Radiotherapy in Treatment for Hepatocellular Carcinoma” / Invited speaker and Chair of Session: Multidisciplinary Approaches in Liver Cancer  
 The 26th Annual World Congress of the IASGO, Seoul, Korea (IASGO)
- 2016 “GI Cancer Therapy with Targeted Agents: Lessons from Translational Studies” / State-of-the-Art Plenary Lecture  
 The 26th Annual World Congress of the IASGO, Seoul, Korea (IASGO)
- 2016 “Chemotherapy strategy for colorectal liver metastases” / Invited speaker  
 The E-AHPBA/IASGO Joint Postgraduate Course, Lyon, France (University of Lyon)
- 2016 “HBP Cancer Therapy: Lessons from Translational Studies” / Invited speaker

- The 2016 HBPSurG Meeting, Lyon, France
- 2017 “Improving outcomes in oncology using biomarkers” / Invited speaker  
GI Oncology Days, Istanbul, Turkey (IASGO/University of Marmara School of Medicine)
- 2017 “New directions in liver cancer treatment” / State-of-the-Art Lecture  
GI Oncology Days, Istanbul, Turkey (IASGO/University of Marmara School of Medicine)
- 2017 “GI cancer therapy with targeted agents: Lessons from translational studies” /Keynote speaker  
IASGO Symposium “Gastrointestinal Tumors – What is New?” Rijeka, Croatia
- 2017 “New systemic therapies for hepatocellular and cholangiocarcinomas” / Invited speaker  
The 12th Cajal Symposium on Translational Research, Bucharest, Romania (Cajal Foundation)
- 2017 “HCC treatment at the intersection between antiangiogenic therapy and immunotherapy” /  
Keynote Speaker  
The 1st Hong Kong International Oncology Forum, Hong Kong (HKIOF)
- 2017 “Using biomarkers to guide antiangiogenic, radiation and immuno-therapies for liver  
cancers” / Visiting Professor Seminar  
University of Freiburg, Germany (University of Freiburg)
- 2017 “Role of translational studies in GI oncology” / Invited speaker and Chair of Session:  
Medical intervention for GI cancer  
7th CME Course of IASGO, Seoul, Korea
- 2017 “Lessons from Translational Studies in Liver Cancers” / Invited speaker and Chair of  
Session: Innovations in Liver Tumor Diagnostics  
IASGO Symposium “Current and Future Perspectives in Primary Liver Tumors”,  
Rotterdam, The Netherlands (Erasmus University, Rotterdam)
- 2017 “New perspectives on the treatment of intractable GI cancers: Role of combination  
therapies” / Invited speaker  
The Keio Medical Society Lecture, Keio University, Tokyo, Japan (Keio University)
- 2017 “New perspectives on the treatment of intractable liver cancers” / Invited speaker  
Invited Seminar, Tohoku University, Sendai, Japan (Tohoku University)
- 2017 “New perspectives on the treatment of liver cancers” / Invited speaker  
Grand Rounds, Sir Run Run Shaw Hospital, Hangzhou, China (Zhejiang University)
- 2017 “The role of translational studies in clinical trials in liver cancers” / Invited speaker  
IASGO PostGraduate Course, “Spinal and GI Surgery and Research”, Luzhou, China
- 2017 “Multidisciplinary approaches to PDAC therapy” / Invited speaker  
IASGO PostGraduate Course, “Spinal and GI Surgery and Research”, Luzhou, China
- 2017 “Updates of clinical trials of systemic treatments for PDA” / Invited speaker  
The 2017 E-AHPBA/IASGO Joint Postgraduate Course, Lyon, France (University of  
Lyon)
- 2017 “Developing new combination therapies for liver cancers” / Invited Speaker  
The 27th Annual World Congress of the IASGO, Lyon, France (IASGO)
- 2018 “Using phase I and II clinical studies to define mechanisms and personalize GI cancer  
therapy” / Invited speaker  
The 13th Cajal Symposium on Translational Research, Bucharest, Romania (Cajal  
Foundation)
- 2018 “Using biomarkers to guide antiangiogenic, radiation and immuno-therapies for GI  
cancers” /Seminar speaker  
Cologne Cancer Club, University of Cologne, Germany
- 2018 “New combination therapies for liver cancers” / Invited speaker

- University of Marmara School of Medicine Onco-Surgical Days, Istanbul, Turkey  
(IASGO/ University of Marmara School of Medicine)
- 2018 “Intercepting pancreatic cancer” / Invited speaker  
University of Marmara School of Medicine Onco-Surgical Days, Istanbul, Turkey  
(IASGO/ University of Marmara School of Medicine)
- 2018 “Biomarkers in cholangiocarcinoma therapy” / Invited speaker  
12th International “Minimal Invasive Surgery” Symposium and 8th CME Course of  
IASGO, Seoul, Korea (Seoul National University)
- 2018 “Lessons from translational oncology studies” / Invited Faculty  
University of Medicine Titu Maiorescu, Bucharest (Romanian Government)
- 2018 “New combination therapies for liver cancers” / Invited Speaker  
The 28th Annual World Congress of the IASGO, Moscow, Russia (IASGO)
- 2018 “New combination therapies for liver cancers” / Invited speaker  
2nd Annual Meeting of the IASGO Egyptian Chapter, Cairo, Egypt (IASGO/ University  
of Mansoura)
- 2019 “A New Era in the Systemic Therapy of HCC: What is the Scientific Basis?” Invited  
speaker  
7th International Onco-Surgical Days, Istanbul, Turkey (IASGO/ University of Marmara  
School of Medicine)
- 2019 “Beyond surgery and chemotherapy for PDAC treatment” / Invited speaker  
7th International Onco-Surgical Days, Istanbul, Turkey (IASGO/ University of Marmara  
School of Medicine)
- 2019 “Beyond surgery and cytotoxics: Targeting stromal vulnerabilities for gastrointestinal  
cancer treatment” / Invited speaker and Chair of Round Table III - Colo-rectal cancers –  
updates  
8th Congress of the Romanian Society of Coloproctology, Iasi, Romania (RSCP/IASGO)
- 2019 “Biomarkers in lung cancer” / Invited speaker  
8th Langendorff Symposium “Lung Cancer: Innovative Diagnosis and Treatment”  
Freiburg, Germany (University of Freiburg)
- 2019 “The Promise and Perils of Combination Therapies Involving Immunotherapy: A Liver  
Cancer Perspective” / Seminar speaker  
Cells-in-Motion Lecture Series, University of Münster, Germany (University of Münster)
- 2019 “Stromal vulnerabilities in liver cancers” / Keynote speaker and Chair of Session –  
Hallmarks of Cancer  
3rd Stop Cancer Symposium, Bucharest, Romania
- 2019 “The role of translational studies in clinical trials in liver cancers” / Invited speaker  
2nd IASGO PostGraduate Course, “Surgery and Research: Osteoporosis, Trauma, Spinal  
and Hepatobiliary and Pancreatic Diseases”, Luzhou, China
- 2019 “Rapidly evolving strategies for the treatment of liver cancer” / Invited speaker  
The Keio Medical Society Lecture, Keio University, Tokyo, Japan (Keio University)
- 2019 “Targeting stromal vulnerabilities to improve chemotherapy and immunotherapy for liver  
cancers” / Seminar speaker  
Seminar, Tohoku University Sendai, Japan. Host: Professor Michiaki Unno (Tohoku  
Univ.)
- 2019 “Intercepting HBP cancers” / Invited speaker (Special Lecture)  
IASGO Postgraduate Course on Hepato-Pancreatico-Biliary Surgery and Oncology,  
Tokyo, Japan (IASGO/Dokkyu University of School of Medicine)
- 2019 “Rapidly evolving strategies for the treatment of primary liver cancers” / Invited speaker  
The 10th Asia-Pacific Primary Liver Cancer Expert Meeting Sapporo, Japan (APPLE)
- 2019 “New approaches to early intervention in pancreatic cancer” / Invited speaker

- IASGO Verona Expert International Meeting on Evolving Strategies in the Management of Liver Metastases, Verona, Italy (University of Verona Medical School)
- 2019 “Rapidly evolving strategies for liver cancer treatment” / Invited faculty  
1st IASGO PostGraduate Course, “Tips and Tricks in HPB surgery”, Belgrade, Serbia
- 2019 “The Role of Correlative Studies in Clinical Trials in Improving Outcomes in HBP Malignancies” / Invited faculty  
1st IASGO PostGraduate Course, “HBP Surgery and Research”, Iasi, Romania
- 2019 “Rapidly evolving strategies for liver cancer treatment” / Invited speaker  
Congress of the Romanian Association Hepato-Bilio- Pancreatic Surgery and Liver Transplantation, Iasi, Romania
- 2019 “Using translational studies to improve outcomes in liver and pancreatic cancers” / Faculty  
MiMT Program, Luohe Hospital, Louhe, China (MiMT)
- 2019 “Using biomarkers to guide antiangiogenic, radiation and immuno-therapies for intractable GI cancers” / Invited speaker  
Seminar at Simcere Pharma, Nanjing, China (Simcere)
- 2019 “Rapidly evolving strategies for liver cancer treatment” / Invited speaker  
Seminar in the Department of Liver Surgery, Sun Yat-sen University, Guangzhou, China (Sun Yat-sen University) (Host: Prof. Kuang)
- 2019 “Anticancer treatments of tomorrow in GI Oncology” / Keynote Speaker  
The 29th Annual World Congress of the IASGO, Bangkok, Thailand (IASGO)
- 2019 “New trends in systemic treatment of gastric cancer” / Faculty  
The 1st IASGO CME HBP Course, Braga, Portugal (University of Braga)
- 2019 “Liver metastases from colorectal cancer” / Faculty  
The 1st IASGO CME HBP Course, Braga, Portugal (University of Braga)
- 2019 “Using translational studies to achieve earlier interception of aggressive GI cancers” / Invited speaker  
The XXVIII Latin-American Congress on Surgery – FELAC 2019 and the LXX Uruguayan Congress on Surgery, Montevideo, Uruguay (FELAC)
- 2020 “New combination therapies for liver cancers and their scientific basis” / Invited speaker  
The 120th Meeting of the Japanese Society of Surgery, Yokohama, Japan (virtual)
- 2020 “Rapidly evolving strategies for cholangiocarcinoma treatment” / Invited speaker  
The International Association of Surgeons, Gastroenterologists and Oncologists (IASGO) and the Korean Society of Gastrointestinal Cancer (KSGC) Joint Symposium IK2020 (virtual)
- 2020 “Rapidly evolving therapies in liver cancers” / Invited Speaker  
4th Stop Cancer Symposium (webinar), Romania
- 2020 “How do we make progress in PDAC therapy?” / Invited faculty  
Onco-Surgical Days Webinar Series – PDAC (IASGO/ University of Marmara School of Medicine, Turkey)
- 2020 “Modelling human disease in preclinical models to improve the efficacy of immunotherapy in cancer patients” / Invited Webinar  
Department of Zoology, Mar Ivanios College and Kerala State Higher Education Council, India
- 2020 “New treatments for liver cancers” / Keynote Speaker  
IASGO Egyptian Chapter “International Live Webinars - Advanced Approach”, Egypt (IASGO)
- 2020 “Rapidly evolving strategies for the treatment of liver cancer” / Invited Speaker  
CONFER 2000, Regional Institute of Oncology, Iasi, Romania (virtual)
- 2020 “Revisiting the century-old “Seed and Soil” theory on tumor metastasis” / Invited Speaker  
4th Stop Cancer Symposium, Romania (virtual)

- 2020 “The evolution of translational oncology studies in the era of molecular targeted therapies” / State-of-the-art Lecture  
10th Congress of the Romanian Society of Coloproctology, Iasi, Romania (RSCP/IASGO) (virtual)
- 2020 “New insights into the rapidly evolving treatment paradigms for HCC” / Invited faculty & Chair  
Onco-Surgical Days Webinar Series – HCC “What’s next?” (IASGO/ University of Marmara School of Medicine, Turkey) (webinar)
- 2021 “Rapidly evolving strategies for liver cancer treatment” / Invited faculty  
2nd IASGO Belgrade Congress, “Tips and Tricks in Multidisciplinary Management of HPB Cancers”, Belgrade, Serbia (webinar)
- 2021 “Liver cancer treatment: from translational research to clinical practice” / Invited speaker  
The 2021 HBPSurG Meeting, Lyon, France (online)

### **Report of Technological and Other Scientific Innovations**

- 2015 “*Anti-CXCR4 As A Sensitizer to Cancer Therapeutics*”  
US Patent No. 9,155,723, Oct 13, 2015  
As a member of the Steele Laboratories for Tumor Biology, my colleagues and I identified and demonstrated the use of CXCR4 pathway inhibition as a sensitizer for anti-cancer treatments such as radiation, chemotherapy, and targeted therapies. This use of these agents has since been used/validated by multiple labs in the US and abroad.
- 2017 “*Triple Negative Breast Cancer Treatment Method*”  
US Patent WO2017184597A1  
Dr. Tolaney and I identified cabozantinib as an immune-modulator in triple-negative breast cancer patients, as demonstrated by increased fractions of T and NK cells in the blood circulation.
- 2019 “*Classification and Treatment of Gastric Cancer*”  
US Patent 2019 49 453A1  
As a member of the “Esophago-gastric Cancer Interest Group” at MGH, my colleagues and I identified and demonstrated the use of a simplified protein and mRNA-based signature to classify gastric cancers.

### **Report of Education of Patients and Service to the Community**

- No presentations below were sponsored by 3<sup>rd</sup> parties/outside entities
- Those presentations below sponsored by outside entities are so noted and the sponsor(s) is (are) identified.

### **Activities**

- 2011 Relay for Life Training Program / Invited Speaker  
Training of volunteers in North Attleboro, MA, Massachusetts American Cancer Society (ACS)
- 2011 Relay for Life of Billerica / Invited Speaker



	Guest speaker at the Fight Back Ceremony at the Relay For Life of Billerica, Billerica, MA, Massachusetts ACS Organization
2013	Bicycles Battling Cancer ride / Invited Speaker Guest speaker, Fundraisers/Participants, Marlboro, MA, ACS New England Division
2014	American Cancer Society Boston research Dinner / Participant Fundraisers/Participants, Boston, MA, ACS New England Division
2015	1 <sup>st</sup> Kathy's Gala of Hope / Participant Fundraisers/Participants, Woburn, MA, Granara-Skerry Trust
2015	Pancreatic Cancer Action Network (PanCan) Breakfast / Participant Fundraisers/Participants, Cambridge, MA, PanCan
2016	2 <sup>nd</sup> Kathy's Gala of Hope / Participant and Awardee Speaker Fundraisers/Participants, Burlington, MA, Granara-Skerry Trust

## **Report of Scholarship**

### **Peer-Reviewed Scholarship in print or other media:**

#### **Research Investigations**

1. Motoi F, Sunamura M, Ding L, **Duda DG**, Yoshida Y, Zhang W, Matsuno S, Hamada H. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. *Human Gene Therapy* 2000; 11: 223-35.
2. **Duda DG**, Sunamura M, Lozonschi L, Kodama T, Egawa S, Matsumoto G, Shimamura H, Shibuya K, Takeda K, Matsuno S. Direct in vitro evidence and in vivo analysis of the anti-angiogenesis effects of Interleukin 12. *Cancer Research* 2000; 60: 1111-6.
3. Sunamura M, Son L, Lozonschi L, **Duda DG**, Kodama T, Matsumoto G, Shimamura H, Takeda K, Kobari M, Hamada H, Matsuno S. The anti-angiogenesis effect of IL-12 during the early growth of human pancreatic cancer in SCID mice. *Pancreas* 2000; 20: 227-33.
4. Ding L, Sunamura M, Kodama T, Yamauchi J, **Duda DG**, Shimamura H, Shibuya K, Takeda K, Matsuno S. In vivo evaluation of the early events associated with liver metastasis of circulating cancer cells. *British Journal of Cancer* 2001; 85: 431-8.
5. Sunamura M, **Duda DG**, Shimamura H, Motoi F, Yatsuoka T, Shibuya K, Takeda K, Matsuno S. Tumor dormancy therapy using genetically engineered drug delivery system. *Japanese Journal of Gastroenterology and Surgery* 2001; 34: 425-30.
6. **Duda DG**, Sunamura M, Lozonschi L, Yokoyama T, Yatsuoka T, Motoi F, Horii A, Tani K, Asano S, Nakamura Y, Matsuno S. Overexpression of the p53-inducible Brain Angiogenesis Inhibitor 1 suppresses efficiently tumor angiogenesis *British Journal of Cancer* 2002; 85: 490-7.
7. Lefter LP, Furukawa T, Sunamura M, **Duda DG**, Takeda K, Kotobuki N, Oshimura M, Matsuno S, Horii A. Silencing the tumorigenic phenotype by Chromosome 18 transfer into pancreatic cancer cell lines. *Genes Chromosomes Cancer* 2002; 34: 234-42.
8. Hoshida T, Sunamura M, **Duda DG**, Egawa S, Miyazaki S, Shineha R, Hamada H, Ohtani H, Satomi S, Matsuno S. Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 VEGFR. *Pancreas* 2002; 25: 111-21.
9. Sunamura M, **Duda DG**, Ghattas MH, Lozonschi L, Motoi F, Yamauchi J, Matsuno S, Shibahara S, Abraham NG. Heme Oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. *Angiogenesis* 2003; 6: 25-30.
10. **Duda DG**, Sunamura M, Lefter LP, Furukawa T, Yokoyama T, Yatsuoka T, Abe T, Inoue H, Motoi F, Egawa S, Matsuno S, Horii A. SMAD4 restoration by gene therapy reverses the invasive phenotype in pancreatic cancer cells. *Oncogene* 2003; 22: 6855-62.

11. Fukumura D\*, Ushiyama A\*, **Duda DG\***, Xu L, Tam J, Chatterjee VKK, Garkavtsev I, Jain RK. Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. *Circulation Research* 2003; 93: e88-97. \* Equal first authors.
12. Sunamura M, Lefter LP, **Duda DG**, Morita R, Inoue H, Yokoyama T, Yatsuoka T, Abe T, Egawa S, Furukawa T, Fukushige S, Oshimura M, Horii A, Matsuno S. The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma. *Pancreas* 28, 2004; 28: 311-6.
13. Willett CG, Boucher Y\*, di Tomaso E\*, **Duda DG\***, Munn LL\*, Tong RT\*, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivasular effects in human rectal cancer. *Nature Medicine* 2004; 10: 145-7. PMID: PMC2693485. \* Equal contribution.
14. **Duda DG**, Fukumura D, Munn LL, Booth MF, Brown EB, Huang P, Seed B, Jain RK. Differential transplantability of tumor-associated stromal cells. *Cancer Research* 2004; 63, 5920-4.
15. Willett CG, Boucher Y, **Duda DG**, di Tomaso E, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Cohen KS, Petit L, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY, Jain RK. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radio-chemotherapy: Continued experience of a phase I trial in rectal cancer patients. *Journal of Clinical Oncology* 2005; 23: 8136-9.
16. Stroh M, Zimmer JP, **Duda DG**, Levchenko TS, Cohen KS, Scadden DT, Torchilin VP, Bawendi MG, Fukumura D, Jain RK. Quantum Dots spectrally distinguish multiple species within the tumor milieu in vivo. *Nature Medicine* 2005; 11: 678-82.
17. Saito Y, Sunamura M, Motoi F, Abe H, Egawa S, **Duda DG**, Hoshida T, Fukuyama S, Hamada H, Matsuno S. Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region. *Cancer Gene Therapy* 2006; 13: 242-52.
18. Kisucka J, Butterfield CE, **Duda DG**, Eichenberger SC, Saffaripour S, Ware J, Ruggeri ZM, Jain RK, Folkman J, Wagner DD. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. *Proceedings of the National Academy of Science USA* 2006; 103:855-60.
19. **Duda DG**, Cohen KS, Kozin SV, JY Perentes, Fukumura D, Scadden DT, Jain RK. Evidence for bone marrow-derived endothelial cells incorporation into perfused blood vessels in tumors. *Blood* 2006; 107: 2774-6. PMID: PMC1895376.
20. **Duda DG\***, Cohen KS, di Tomaso E, Au P, Klein RJ, Scadden DT, Willett CG, Jain RK. Differential CD146 expression on circulating versus tissue endothelial cells: Implications for circulating endothelial cells as biomarker for antiangiogenic therapy. *Journal of Clinical Oncology* 2006; 24: 1449-53. \* Corresponding author.
21. Batchelor TT<sup>#</sup>, Sorensen AG<sup>#</sup>, di Tomaso E\*, Zhang W-T\*, **Duda DG\***, Cohen KS, Kozak KR, Cahill DP, Chen P-J, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. *Cancer Cell* 2007; 11: 83-95. PMID: PMC2748664. <sup>#</sup>and \* Equal contribution.
22. **Duda DG**, Cohen KS, Scadden DT, Jain RK. A protocol for detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. *Nature Protocols* 2007; 4:805-10.
23. Au P, Daheron LM, **Duda DG**, Cohen KS, Tyrrell JA, Fukumura D, Scadden DT, Jain RK. Differential in vivo potential of human endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. *Blood* 2008; 111: 1302-5.
24. Jones R, Capen D, Petersen B, Jain RK, **Duda DG**. A protocol for a lung neovascularization model in rodents. *Nature Protocols* 2008; 3: 378-87.
25. Jones R, Capen D, Cohen KS, Munn LL, Jain RK, **Duda DG**. A protocol for phenotypic detection and characterization of vascular cells in a lung neovascularization model in rodents. *Nature Protocols* 2008; 3: 388-97.

26. Huang P, **Duda DG**, Jain RK, Fukumura D. Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice. *Comparative Medicine* 2008; 58: 253-63.
27. Tam J\*, **Duda DG\***, Perentes JY\*, Quadri RS, Fukumura D, Jain RK. Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: Role of local versus bone marrow-derived endothelial cells. *PLoS One* 2009; 4: e4974. \* Equal first authors.
28. Kamoun W, Ley CD, Farrar C, Duyverman A, Lacorre D, Lahdenranta J, di Tomaso E, **Duda DG**, Munn L, Fukumura D, Sorensen G, Jain RK. Edema control by anti-VEGF therapy prolongs survival despite persistent brain tumor growth in mice. *Journal of Clinical Oncology* 2009; 27: 2542-52.
29. Jones R, Capen D, Jacobson M, Cohen KS, Scadden DT, **Duda DG**. VEGFR2<sup>+</sup>PDGFRβ<sup>+</sup> circulating precursor cells participate in lung capillary repair after hyperoxia-induced lung injury (HALI). *Journal of Cellular and Molecular Medicine* 2009; 13: 3720-9.
30. Zhu AX\*, Sahani DV\*, **Duda DG\***, di Tomaso E, Ancukiewicz M, Catalano O, Sindhvani V, Blaszkowsky LS, Yoon SS, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. *Journal of Clinical Oncology* 2009; 27: 3027-35. PMID: PMC2702235. \* Equal first authors.
31. Willett CG\*, **Duda DG\***, di Tomaso E\*, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito PC, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK. Efficacy, safety and biomarkers of neoadjuvant bevacizumab, radiation therapy and 5-Fluorouracil in rectal cancer: A multidisciplinary phase II study. *Journal of Clinical Oncology* 2009; 27: 3020-6. \* Equal first authors.
32. Au P, Tam J, **Duda DG**, Fukumura D, Jain RK. Paradoxical effects of PDGF-BB overexpression in endothelial cells on engineered blood vessels *in vivo*. *American Journal of Pathology* 2009; 175: 294-302.
33. Sorensen AG, Batchelor TT, Zhang W-T, Chen P-J, Yeo P, Wang M, Jennings D, Wen PY, Ancukiewicz M, Lahdenranta J, di Tomaso E, **Duda DG**, Jain RK. A "Vascular Normalization Index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. *Cancer Research* 2009; 69: 5296-300.
34. Dawson MR, Duda DG, Fukumura D, Jain RK. VEGFR1-activity-independent metastasis formation. *Nature* 2009; 461: E4-5. PMID: PMC3065241.
35. Dawson MR\*, **Duda DG\***, Chae S-S, Fukumura D, Jain RK. VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation. *PLoS One* 2009; 4: e6525. \* Equal first authors.
36. Xu L\*, **Duda DG\***, di Tomaso E\*, Ancukiewicz M, Chung DC, Lauwers GY, Samuel R, Shellito PC, Czito B, Poleski M, Bentley R, Clark JW, Willett CG, Jain RK. Direct evidence that bevacizumab, an anti-VEGF antibody, upregulates SDF1α, CXCR4, CXCL6 and neuropilin 1 in tumors in rectal cancer patients. *Cancer Research* 2009; 69: 7905-10. PMID: PMC2859041. \* Equal first authors.
37. Batchelor TT, **Duda DG**, di Tomaso E, Ancukiewicz M, Plotkin SR, Eichler A, Gerstner ER, Chea H, Hochberg FH, Louis DN, Cohen KS, Ivy P, Drappatz J, Exarhopoulos A, Moses MA, Wen PY, Sorensen AG, Jain RK. Phase II study of cediranib, an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. *Journal of Clinical Oncology* 2010; 28: 2817-23. PMID: PMC2903316.
38. **Duda DG**, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, Bentley R, Poleski M, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito PC, Clark JW, Jain RK. Plasma soluble VEGFR1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. *Oncologist* 2010; 15: 577-83. PMID: PMC3061828.
39. Kozin SV, Kamoun W, Huang Y, Dawson MR, Jain RK, **Duda DG**. Recruitment of myeloid but not endothelial precursor cells facilitates tumor re-growth after local irradiation. *Cancer Research* 2010; 70: 5679-85. PMID: PMC2918387.
40. Willett CG\*, **Duda DG\***, Ancukiewicz M\*, Shah M, Czito BG, Bentley R, Poleski M, Fujita H, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito PC, Chung DC, Clark JW, Jain RK. A safety and

survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared to standard chemoradiation in locally advanced rectal cancer. *Oncologist* 2010b; 15: 845-51. \* Equal first authors.

41. **Duda DG**, Duyverman AMMJ, Kohno M, Steller EJA, Fukumura D, Jain RK. Malignant cells facilitate lung metastasis by bringing their own soil. *Proceedings of the National Academy of Science U S A* 2010; 107: 21677-82.
42. Dawson MR, Chae S-S, Jain RK, **Duda DG**. Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression. *American Journal of Cancer Research* 2011; 1:144-54.
43. di Tomaso E\*, Snuderl M\*, Kamoun W\*, **Duda DG**, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte T, Sorensen AG, Batchelor TT, Jain RK. Glioblastoma recurrence after cediranib therapy in patients: Lack of "rebound" revascularization as mode of escape. *Cancer Research* 2011; 71: 17-28. PMID: PMC3074948. \* Equal first authors.
44. Hiratsuka S\*, **Duda DG\***, Huang Y, Goel S, Sugiyama T, Nagasawa T, Fukumura D, Jain RK. C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation-antigen (Gr-1) positive cells. *Proceedings of the National Academy of Science U S A* 2011; 108: 302-7. PMID: PMC3017172. \* Equal first authors.
45. Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, **Duda DG**, Wen PY, Jain RK, Batchelor TT. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. *Journal of Neuro-oncology* 2011; 103: 325-32.
46. Zhu AX\*, **Duda DG\***, Ancukiewicz M, di Tomaso E, Clark JW, Miksad RA, Fuchs CS, Ryan DP, Jain RK. Exploratory analysis of sunitinib toxicity in advanced hepatocellular carcinoma: Kinetics and potential biomarker value. *Clinical Cancer Research* 2011; 17: 918-27. PMID: PMC3023846. \* Equal first authors.
47. Hiratsuka S, Goel S, Kamoun W, Fukumura D, **Duda DG\***, Jain RK\*. Endothelial focal adhesion kinase mediates cancer cell homing to discrete foci in lungs. *Proceedings of the National Academy of Science U S A* 2011; 108: 3725-30. \* Corresponding authors.
48. Horowitz NS\*, Penson RT\*, **Duda DG\***, di Tomaso E\*, Boucher Y, Ancukiewicz M, Cohen KS, Berlin S, Krasner C, Moses MA, Jain RK. Safety, efficacy and biomarker exploration in a phase II study of bevacizumab, oxaliplatin and gemcitabine in recurrent Müllerian carcinoma. *Clinical Ovarian Cancer* 2011; 4: 26-33. \* Equal first authors.
49. Yoon SS, **Duda DG**, Karl DL, Kim T-M, Kambadakone AR, Chen Y-L, Rothrock C, Rosenberg AE, Nielsen GP, Kirsch DG, Choy E, Harmon DC, Hornicek FJ, Dreyfuss J, Ancukiewicz M, Sahani DV, Park PJ, Jain RK, DeLaney DF. Phase II study of neoadjuvant bevacizumab and radiation therapy for resectable soft tissue sarcomas. *International Journal of Radiation Oncology, Biology and Physics* 2011; 81: 1081-90.
50. Saylor PJ, Kozak RK, Smith MR, Ancukiewicz M, Efstathiou JA, Zietman AL, Jain RK, **Duda DG**. Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. *Oncologist* 2012; 17: 212-9. PMID: PMC3286170.
51. Raut CP\*, Boucher Y\*, **Duda DG\***, Morgan JA, Quek R, Ancukiewicz M, Lahdenranta J, Eder JP, Demetri GD, Jain RK. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI Protocol 6948). *PLoS ONE* 2012; 7: e26331. PMID: PMC3274514. \* Equal first authors.
52. Duyverman AMMJ, Kohno M, Roberge S, Fukumura D, **Duda DG**, Jain RK. An isolated tumor perfusion model in mice. *Nature Protocols* 2012; 7: 749-55. PMID: PMC3375334.
53. Duyverman AMMJ, Steller JA, Fukumura D, Jain RK, **Duda DG**. Studying primary tumor-associated fibroblast involvement in cancer metastasis in mice. *Nature Protocols* 2012; 7: 756-62. PMID: PMC3380105.
54. Duyverman AMMJ, Kohno M, **Duda DG**, Jain RK, Fukumura D. A transient parabiosis skin transplantation model in mice. *Nature Protocols* 2012; 7: 763-70. PMID: PMC3375333.

55. Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkiwsky L, Elliott M, Regan E, Jain RK, **Duda DG**. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastatic colorectal cancer. *PLoS One* 2012; 7: e38231. PMID: PMC3373492.
56. Dima SO, Tanase C, Albuiescu R, Herlea V, Chivu-Economescu M, Purnichescu-Purtan R, Dumitrascu T, **Duda DG**, Popescu I. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. *Pancreas* 2012; 41: 1001–7.
57. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Vianello F, Leblanc P, Munn LL, Huang P, **Duda DG**, Fukumura D, Jain RK, Poznansky MC. Vascular normalizing dose of antiangiogenic treatment reprograms the immunosuppressive tumor microenvironment and potentiates a vaccine therapy. *Proceedings of the National Academy of Science USA* 2012; 109: 17561-6. PMID: PMC3491458.
58. Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkiwsky LS, Meyerhardt JA, Abrams TA, McCleary NJ, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, **Duda DG**. Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study. *Clinical Cancer Research* 2013; 19: 1157-66. PMID: PMC3609423.
59. Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Riedemann L, Walsh EC, Anolik R, Huang Y, Martin JD, Kamoun W, Knevels E, Schmidt T, Vakoc BJ, Mohan N, Chung E, Roberge S, Peterson T, Niemeyer E, **Duda DG**, Fukumura D, Xu L, Carmeliet P, Jain RK. Placental growth factor/neuropilin 1 signaling is required for medulloblastoma growth. *Cell* 2013; 152: 1065-76. PMID: PMC3587980
60. Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, Riedemann L, Ivy P, **Duda DG**, Ancukiewicz M, Plotkin SR, Chi AS, Gerstner ER, Eichler AF, Dietrich J, Stemmer-Rachamimov A, Batchelor TT, Jain RK. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival in recurrent glioblastoma patients. *Neurooncology* 2013; 15: 1079-87. PMID: PMC3714160.
61. Sahani DV, Jiang T, **Duda DG**, Catalano OA, Ancukiewicz M, Jain RK, Zhu AX. Magnetic resonance imaging biomarkers in hepatocellular carcinoma: Association with response and circulating biomarkers after sunitinib therapy. *Journal of Hematology & Oncology* 2013; 6: 51. PMID: PMC3722053.
62. Samuel R, Daheron L, Liao S, Kamoun WS, Vardam T, Batista A, Buecker C, Schäfer R, Han X, Au P, Scadden DT, **Duda DG**, Fukumura D, Jain RK. Generation of functionally competent durable engineered blood vessels from human induced pluripotent stem cells. *Proceedings of the National Academy of Science USA* 2013; 110: 12774-9. PMID: PMC3732948.
63. Goel S, Gupta N, Walcott BP, Snuderl M, Kirkpatrick ND, Heishi T, Huang Y, Kesler C, Martin JD, Ager E, Samuel R, Wang S, Yazbek J, Vakoc BJ, Peterson RT, Padera TP, **Duda DG**, Fukumura D, Jain RK. Tie-2 activation by a Vascular-Endothelial Protein Tyrosine Phosphatase Inhibitor normalizes breast cancer vasculature and delays metastatic progression. *Journal of the National Cancer Institute* 2013; 105: 1188-201. PMID: PMC3748004.
64. Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent FW, **Duda DG**, Stuart K. A phase II and biomarker study of ramucirumab, a fully human monoclonal antibody targeting the vascular endothelial growth factor receptor-2, as first-line monotherapy in patients with advanced hepatocellular carcinoma. *Clinical Cancer Research* 2013; 19: 6614-23. PMID: In process.
65. Chan-on W, Nairismägi M-L, Ong CK, Dima SO, Pairojkul C, Lim KH, McPherson JR, Lim WK, Cutcutache I, Heng HL, Ooid L, Chung A, Chow P, Cheow PC, Yee LS, Huat ITB, **Duda DG**, Nastase A, Myint SS, Wong BH, Gan A, Yu W, Rajasegaran V, Ng CCY, Huang DC, Yongvanit P, Wongkham S, Khuntikeo N, Bhudhisawasdi V, Popescu I, Rozen SG, Tan P, Teh BT. Distinct mutational patterns of infection and non-infection-related bile duct cancers revealed by exome sequencing. *Nature Genetics* 2013; 45: 1474-8. PMID: 24185513. PMID: In process.

66. Batchelor TT\*, Gerstner ER\*, Emblem KE\*, **Duda DG\***, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho M, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Bo-Moon C, Iafrate AJ, Rosen B, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Improved perfusion and oxygenation due to vascular normalization improves survival in glioblastoma patients treated with cediranib and chemoradiation. *Proceedings of the National Academy of Science U S A* 2013; 110: 19059-64. PMID: PMC3839699. \*Equal first authors.
67. Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK, **Duda DG**. Differential effects of sorafenib on liver versus tumor fibrosis mediated by SDF1 $\alpha$ /CXCR4 axis and Gr-1+ myeloid cell infiltration in mice. *Hepatology* 2014; 59: 1435-1447. PMID: PMC3966948.
68. Cucu D, Chiritoiu G, Petrescu S, Babes A, Stanica L, **Duda DG**, Horii A, Dima SO, Popescu I. Characterization of functional transient receptor potential melastatin 8 channels in human pancreatic ductal adenocarcinoma cells. *Pancreas* 2014; 43: 795-800. PMID: In process.
69. Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Wo J-Y, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone C, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-del Castillo C, **Duda DG**. A phase I/II and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. *International Journal of Radiation Oncology, Biology and Physics* 2014; 89: 830-8.
70. Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, **Duda DG**. CXCR4 inhibition in tumor microenvironment facilitates anti-PD-1 immunotherapy in sorafenib-treated HCC in mice. *Hepatology* 2015; 61: 1591-602. PMID: PMC4406806.
71. Kambadakone A, Yoon SS, Kim T-M, Karl DL, **Duda DG**, DeLaney TF, Sahani DS. CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: Comparison with tumor morphology, circulating and tumor biomarkers, and gene expression. *American Journal of Roentgenology* 2015 204: W11-8. PMID: PMC4479405.
72. Botezatu A, Bleotu C, Nastase A, Anton G, Bacalbasa N, **Duda DG**, Dima SO, Popescu I. Epigenetic silencing of GNMT gene in pancreatic adenocarcinoma. *Cancer Genomics Proteomics* 2015; 12: 21-30.
73. Han H-S, Niemeyer E, Huang Y, Kamoun WS, Martin J, Bhaumik J, Chen Y, Roberge S, Cui J, Martin MR, Fukumura D, Jain RK, Bawendi M, **Duda DG**. Novel quantum dot/antibody conjugates for *in vivo* cytometric imaging in mice. *Proceedings of the National Academy of Science U S A* 2015; 112: 1350-5. PMID: PMC4321304.
74. Heist RS\*, **Duda DG\***, Sahani DV, Ancukiewicz M, Fidiias P, Sequist LV, Temel JT, Shaw A, Pennell NA, Neal JW, Gandhi L, Lynch TJ, Engelman JA, Jain RK. Improved rather than impaired tumor vasculature after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in non-small cell lung cancer. *Proceedings of the National Academy of Science U S A* 2015; 112: 1547-52. PMID: PMC4321320. \*Equal first authors.
75. Hayano K, Tian F, Kambadakone AR, Yoon SS, **Duda DG**, Ganeshan B, Sahani DV. Texture analysis of non-contrast enhanced CT for assessing angiogenesis and survival of soft tissue sarcoma. *Journal of Computer Assisted Tomography* 2015; 39: 607-12. PMID: PMC4504795.
76. Lee EQ, Kaley TJ, **Duda DG**, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky AM, Ancukiewicz MA, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukheim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon K, Wen PY. A multicenter, phase II, randomized, non-comparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients. *Clinical Cancer Research* 2015; 21: 3610-8.
77. Gerstner ER, Ye X, **Duda DG**, Levine MA, Mikkelsen T, Kaley TJ, Olson JJ, Nabors BL, Ahluwalia M, Wen PY, Jain RK, Batchelor TT, Grossman S. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. *Neurooncology* 2015; 17: 1386-92. PMID: PMC4578584.

78. Jeong H-S, Jones D, Liao S, Wattson DA, Cui C, **Duda DG**, Willett CG, Jain RK, Padera TP. Investigation of the lack of angiogenesis in the formation of lymph node metastases. *Journal of the National Cancer Institute* 2015; 107: pii: djv155.
79. Lemon C, Karnas E, Han X, Bruns O, Fukumura D, Bawendi M, Jain RK, **Duda DG**, Nocera D. Micelle-encapsulated quantum dot-porphyrin assemblies as ratiometric two-photon oxygen sensors. *Journal of the American Chemical Society* 2015; 37: 9832-42.
80. Reiberger T, Chen Y, Ramjiawan RR, Hato T, Fan C, Samuel R, Huang P, Lauwers GY, Zhu AX, Bardeesy N, Jain RK, **Duda DG**. A model of orthotopic hepatocellular carcinoma in mice with underlying liver cirrhosis. *Nature Protocols* 2015; 10: 1264-74.
81. Tolaney SM\*, Boucher Y\*, **Duda DG\***, Martin JD\*, Seano G, Ancukiewicz M, Barry WT, Goel S, Lahdenrata J, Isakoff SJ, Yeh E, Jain SR, Golshan M, Brock J, Snuderl M, Winer EP, Krop IE, Jain RK. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. *Proceedings of the National Academy of Science U S A* 2015; 112: 14325-14330. \*Equal first authors.
82. Askoxylakis V, Ferraro GB, Kodack DP, Badeaux M, Seano G, Kloepper J, Vardam T, Martin JD, Shankaraiah RC, Bezwada D, Qi X, **Duda DG**, Fukumura D, Engelman JA, Jain RK. Ado-Trastuzumab emtansine (T-DM1) is effective against established HER2-positive breast cancer brain metastases in mice. *Journal of the National Cancer Institute* 2016; 108: pii: djv3.
83. Incio J, Tam J, Rahbari NN, Suboj P, McManus D, Chin SM, Vardam-Kaur T, Batista A, Babykutty S, Jung K, Khachatryan A, Hato T, Ligibel J, Krop IE, Puchner SB, Schlett CL, Hoffmann U, Ancukiewicz M, Shibuya M, Carmeliet P, Soares R, **Duda DG**, Jain RK, Fukumura D. PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity. *Clinical Cancer Research* 2016; 22: 2993-3004.
84. Hayano K, Kulkarni NM, **Duda DG**, Heist RS, Sahani DV. Exploration of imaging biomarkers for predicting survival in advanced non-small cell lung cancer patients treated with anti-angiogenic chemotherapy. *American Journal of Roentgenology* 2016; 2:1-7.
85. Peterson TE, Kirkpatrick ND, Huang Y, Farrar CT, Marijt K, Kloepper J, Datta M, Amoozgar Z, Seano G, Jung K, Kamoun WS, Batista A, Vardam T, Snuderl M, Goveia J, Chatterjee S, Muzikansky A, Leow CC, Xu L, Batchelor TT, **Duda DG**, Fukumura D, Jain RK. Dual targeting of Ang-2 and VEGF receptors prolongs survival in glioblastoma by normalizing tumor vessels and reprogramming macrophages. *Proceedings of the National Academy of Science U S A* 2016; 113: 4470-75.
86. Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek KH, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, Askoxylakis V, Taylor JW, Lu-Emerson C, Batista A, Kirkpatrick ND, Jung K, Snuderl M, Muzikansky A, Stubenrauch KG, Krieter O, Wakimoto H, Xu L, Munn LL, **Duda DG**, Fukumura D, Batchelor TT, Jain RK. Dual angiopoietin-2/VEGF inhibition in glioblastoma prolongs survival through reprogramming of macrophages. *Proceedings of the National Academy of Science USA* 2016; 113: 4476-81.
87. Blakeley JO, Ye X, **Duda DG**, Halpin C, Bergner AL, Muzikansky A, Merker VL, Gerstner ER, Fayad L, Ahlawat S, Jacobs M, Jain RK, Zalewski C, Dombi E, Widemann B, Plotkin SR. Efficacy and biomarker study of bevacizumab for hearing loss due to neurofibromatosis type 2 associated vestibular schwannomas. *Journal of Clinical Oncology* 2016; 34: 1669-75.
88. Nastase A, Dima S, Heng HL, Ng CCY, Myint SS, Loh JL, Ong CK, Teh BT, Herlea V, **Duda DG**, Popescu I. Evaluation of KRAS mutational status in pancreatic ductal adenocarcinoma. *Surgery Gastroenterology and Oncology* 2016; 21: 102-8.
89. Setia N, Agoston AT, Han HS, Mullen JT, **Duda DG**, Clark JW, Deshpande V, Mino-Kenudson M, Srivastava A, Lennerz JK, Hong TS, Kwak E, Lauwers GY. A protein and mRNA expression-based classification of gastric cancer. *Modern Pathology* 2016; 29: 772-84.
90. Chng KR, Chan SH, Li C, Jusakul A, Ng A, Wilm A, Tan D, Lim KH, Soetinko R, Chow P, Kiat OC, The BT, **Duda DG**, Dima S, Popescu I, Wongkham C, Yongvanit P, Wongkham S, Bhudhisawasdi V, Khuntikeo N, Tan P, Pairojkul C, Nagarajan N, Ngeow J. Tissue microbiome profiling identifies an

enrichment of specific enteric microbes in *Opisthorchis Viverrini* associated cholangiocarcinoma. *EBioMedicine* 2016; 8:195-202.

91. Dima SO, Chivu-Economescu M, Purnichescu-Purtan R, Nastase A, Bacalbaşa N, Florea R, Bleotu C, Diaconu C, **Duda DG**, Herlea V, Popescu I. MAP4K4 expression is selectively upregulated and increases cell invasion in pancreatic ductal adenocarcinoma. *Surgery Gastroenterology and Oncology* 2016; 21: 32-7.
92. Rahbari NN, Kedrin D, Incio J, Liu H, Ho WW, Nia HT, Edrich CM, Jung K, Daubriac J, Chen I, Heishi T, Martin JD, Huang Y, Maimon N, Reissfelder C, Weitz J, Boucher Y, Clark JW, Grodzinsky AJ, **Duda DG**, Jain RK, Fukumura D. Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases. *Science Translational Medicine* 2016; 8: 360ra135.
93. Nastase A, Dima S, Tica V, Florea R Sorop A, Ilie V, Eftimie M, Paslaru L, Herlea V, Bacalbasu N, Ivan L, Uyy E, Suica VI, Antohe F, Iancu IV, Plesa A, Botezatu A, **Duda DG**, Diaconu CC. S100A4 and ERBB2 as Co-Factors in Pancreatic Cancer. *Surgery Gastroenterology and Oncology* 2016; 21: 259-66.
94. Batchelor TT, Gerstner ER, Ye X, Desideri S, **Duda DG**, Peereboom D, Lesser GJ, Chowdhary S, Wen PY, Grossman S, Supko JG. Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor- $\beta$  tyrosine kinase inhibitor, in patients with recurrent glioblastoma. *Neuro-Oncology* 2017; 19: 567-75.
95. Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Pawletz CP, Demeo MK, Ramaiya NH, Overmoyer BA, Jain RK, Winer E, **Duda DG**. Phase 2 and biomarker study of cabozantinib in metastatic triple-negative breast cancer patients. *Oncologist* 2017; 22: 25-32.
96. Kalpathy-Cramer J, Chandra V, Da X, Ou Y, Emblem KE, Muzikansky A, Cai X, Douw L, Evans JG, Dietrich J, Chi AS, Wen PY, Stufflebeam S, Rosen B, **Duda DG**, Jain RK, Batchelor TT, Gerstner ER. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. *Journal of Neuro-Oncology* 2017; 131: 603-10.
97. Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen J, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, **Duda DG\***, Zhu AX\*. A phase II and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. *Cancer* 2017; 123: 1979-88. \*Senior authors.
98. Nastase A, YaoTeo J, Heng HL, Ng CCY, Myint SS, Rajasegaran V, Loh JL, Lee SY, Ooi LL, Chung AYF, Chow PKH, Cheow PC, Wan WK, Azhar R, Khoo A, Xiu SX, Alkaff SMF, Cutcutache I, Lim JQ, Ong CK, Herlea V, Dima S, **Duda DG**, Teh BT, Popescu I, Lim TKH. Genomic and proteomic characterization of ARID1A chromatin remodeler in ampullary tumors. *American Journal of Cancer Research* 2017; 7: 484-502.
99. Chen Y, Liu Y-C, Sung Y-C, Ramjiawan RR, Lin T-T, Chang C-C, Jeng K-S, Chang C-F, Liu C-H, Gao D-Y, Hsu F-F, Duyverman AM, Kitahara S, Huang P, Dima S, Popescu I, Flaherty KT, Zhu AX, Bardeesy N, Jain RK, Benes CH, **Duda DG**. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. *Scientific Reports* 2017; 7: 44123.
100. Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X-L, Shankaraiah R, Cao AZ, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, Wong C, Kloepper J, Das R, Tam A, Tanboon J, **Duda DG**, Miller RC, Siegel MB, Anders CK, Sanders M, Estrada VM, Schlegel R, Arteaga CL, Brachtel E, Huang A, Fukumura D, Engelman JA, Jain RK. The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. *Science Translational Medicine* 2017; 9(391). pii: eaal4682.
101. Andronesi O, Esmaili M, Borra R, Emblem K, Gerstner E, Pinho M, Plotkin S, Chi A, Eichler A, Dietrich J, Ivy P, Wen PY, **Duda DG**, Jain RK, Rosen B, Sorensen AG, Batchelor TT. Early changes in glioblastoma metabolism measured by MR Spectroscopic Imaging during combination of



- antiangiogenic cediranib and chemoradiation therapy are associated with survival. *npj Precision Oncology* 2017; 1: 20.
102. Jusakul A, Yong CH, Cutcutache I, Lim JQ, Huang MN, Padmanabhan N, Nellore V, Kongpetch S, Ng A, Ng LM, Choo SP, Myint SS, Thanan R, Nagarajan S, Lim WK, Ng CCY, Boot A, Liu M, Ong CK, Rajasegaran V, Lie S, Lim AS-T, Lim TH, Tan J, Liang MJ, Mcpherson J, Khuntikeo N, Bhudhisawasdi V, Yongvanit P, Wongkham S, Totoki Y, Nakamura H, Arai Y, Yamasaki S, Chow P, Chung AYW, Ooi LLPJ, Lim T, Dima S, **Duda DG**, Popescu I, Broet P, Hsieh S-Y, Yu M-C, Scarpa A, Lai J, Luo D, Carvalho AL, Vettore A, Rhee H, Park YN, Alexandrov L, Gordan L, Rozen S, Shibata T, Pairojkul C, Teh BT, Tan P. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. *Cancer Discovery* 2017; 7: 1116–35.
  103. Askoxylakis V, Badeaux M, Roberge S, Batista A, Kirkpatrick N, Snuderl M, Amoozgar Z, Seano G, Ferraro G, Chatterjee S, Xu L, Fukumura D, **Duda DG**, Jain RK. A cerebellar window for intravital imaging of normal and disease states in mice. *Nature Protocols* 2017; 12: 2251–62.
  104. Pinter M, Weinmann A, Worns M-A, Hucke F, Bota S, Marquardt JU, **Duda DG**, Jain RK, Galle PR, Trauner M, Peck-Radosavljevic M, Sieghart W. Use of inhibitors of the renin–angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. *United European Gastroenterology Journal* 2017; 5: 987–96.
  105. Reardon DA, Lassman A, Schiff D, Yunus S, Gerstner ER, Cloughesy T, Quant Lee E, Gaffey SC, Barrs J, Bruno J, Muzikansky A, **Duda DG**, Jain RK, Wen PY. Phase II and biomarker study of trebananib, an angiopoietin blocking peptibody, with and without bevacizumab for recurrent glioblastoma patients. *Cancer* 2017; 124: 1438–48.
  106. Sung Y-C, Liu Y-C, Chao P-H, Chang C-C, Lin T-T, Lin J-A, Cheng H-T, Wang J, Lai CP, Chen L-H, Jin P, Wu AY, Chiang T, Gao D-Y, **Duda DG**, Chen Y. Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. *Theranostics* 2018; 8: 894–904.
  107. Incio J, Ligibel JA, McManus DT, Suboj P, Jung K, Kawaguchi K, Pinter M, Babykutty S, Chin SM, Vardam TD, Huang Y, Rahbari NN, Roberge S, Wang D, Gomes-Santos IL, Puchner SB, Schlett CL, Hoffman U, Ancukiewicz M, Tolaney SM, Krop IE, **Duda DG**, Boucher Y, Fukumura D, Jain RK. Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. *Science Translational Medicine* 2018; (10): eaag0945.
  108. Grassberger C, Hong TS, Hato T, Yeap B, Wo J, Tracy M, Bortfeld T, Wolfgang J, Eyler C, Goyal L, Clark JW, Crane CH, Koay EJ, Cobbold M, DeLaney TF, Jain RK, Zhu AX, **Duda DG**. Differential Association between circulating lymphocyte populations with outcome of radiotherapy in subtypes of liver cancer. *International Journal of Radiation Oncology, Biology and Physics* 2018; 101: 1222-5.
  109. Quant Lee E\*, **Duda DG\***, Muzikansky A, Gerstner ER, Kuhn JG, Reardon DA, Nayak L, Norden AD, Doherty L, LaFrankie D, Stefanik J, Vardam T, Smith KH, McCluskey C, Gaffey S, Batchelor TT, Jain RK, Wen PY. Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma. *Clinical Cancer Research*; 2018; 24: 4643-9. \*Equal first authors.
  110. Hong TS, Grassberger C, Yeap B, Jiang W, Wo JY, Goyal L, Clark JW, Crane CH, Koay EJ, Dima S, Eyler C, Popescu I, DeLaney TF, Zhu AX, **Duda DG**. Pretreatment plasma hepatocyte growth factor as biomarker for susceptibility to radiation-induced liver dysfunction in liver cancer patients treated with radiotherapy. *npj Precision Oncology* 2018; 2: 22.
  111. Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Knowles M, Galway A, Afflitto A, Dinicola JF, Maurer JR, Regan E, Jain RK, Mamessier-Birnbaum E, **Duda DG\***, Zhu AX\*. A phase II and biomarker study of sorafenib combined with FOLFOX in patients with advanced hepatocellular carcinoma. *Clinical Cancer Research* 2019; 25: 80-89. \*Co-Senior authors.
  112. Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, **Duda DG**, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen AG, Rosen BR, Gerstner ER. Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. *Scientific Reports* 2018; 8: 17062.

113. Li S, Li W, Leung C-H, Kitahara S, Liu Y, Klein S, Fukumura D, Loeffler JS, Jain RK, **Duda DG\***, Huang P\*. Combining the Angiotensin Receptor Blocker Losartan and the CXCR4 Inhibitor AMD3100 Increases the Efficacy of Radiotherapy in a Metastatic Osteosarcoma Mouse Model. *Journal of Cancer Science & Therapy* 2018; 10: 351-65.
114. Askoxylakis V, Ferraro GB, Badeaux M, Kodack DP, Kirst I, Shankaraiah RC, Wong CSF, **Duda DG**, Fukumura D, Jain RK. Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer. *npj Precision Breast Cancer* 2019; 5:4
115. Richter C, Andronesi OC, Borra RJH, Voigt F, Löck S, **Duda DG**, Guimaraes A, Hong TS, Bortfeld TR, Seco J. Inter-patient variations of radiation-induced normal-tissue changes in Gd-EOBDTPA-enhanced hepatic MRI scans during fractionated proton therapy. *Clinical and Translational Radiation Oncology* 2019; 18:113-9.
116. Kaseb AO, Dima S, Carmagnani Pestana R, Ancukiewicz A, Cucu D, Sorop A, Florea R, Bacalbasa N, Tomescu D, Herlea V, Tanase C, Popescu I, **Duda DG**. An observational study of circulating plasma and serum insulin-like growth factor 1 as prognostic biomarker in surgical hepatocellular carcinoma patients. *Surgery, Gastroenterology and Oncology* 2019; 24: 73-9.
117. Cleary JM, Horick NK, McCleary NJ, Abrams TA, Yurgelun MB, Azzoli CG, Rubinson DA, Brooks G, Chan JA, Blaszkowsky LS, Clark JW, Goyal L, Meyerhardt JA, Ng K, Schrag D, Savarese DMF, Graham C, Gibb KA, Boucher Y, **Duda DG**, Jain RK, Fuchs CS, Enzinger PC. FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma (ZAMEGA): a double blind randomized multi-center phase 2 trial. *Cancer* 2019; 125: 2213-21.
118. Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Blaszkowsky LS, Ferrone CR, Parikh A, Weekes CD, Nipp R, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Lillemoe KD, Jain RK, DeLaney TF, **Duda DG**, Boucher Y, Fernandez-del Castillo C, Hong TS. A phase II study of neoadjuvant FOLFIRINOX in combination with losartan followed by chemoradiotherapy in locally advanced pancreatic cancer: R0 resection rate and clinical outcomes. *JAMA Oncology* 2019; 5: 1020-7.
119. Saftoiu A, Bhutani MS, Itoi T, Arcidiacono PG, Bories E, Cazacu IM, Constantin A, Coronel E, Dietrich CF, **Duda DG**, Garcia JI, Hocke M, Ignee A, Jenssen C, Jinga M, Khor C, Oppong KW, Pereira S, Petrone MC, Santo E, Seicean A, Seo DW, Siyu S, Vilmann P, Waxman I, Yeaton P. Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer (PEACE): A study protocol. *Endoscopic Ultrasound* 2019; 8: 235-40.
120. Lee EQ, Muzikansky A, **Duda DG**, Gaffey S, Reardon DA, Dietrich J, Nayak L, Chukwueke UN, Beroukhim R, Doherty L, Kane C, LaFrankie D, Fontana B, Stefanik J, Ruland S, Caruso V, Bruno J, Ligon K, Wen PY. Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. *Cancer Medicine* 2019; 8: 5988-94.
121. Plotkin SR, **Duda DG**, Muzikansky A, Allen J, Blakeley J, Rosser T, Campian JL, Clapp DW, Fisher MJ, Tongsgard J, Ullrich N, Thomas C, Cutter G, Korf B, Packer P, Karajannis MA. Multicenter prospective phase II and biomarker study of high dose bevacizumab as induction therapy in neurofibromatosis type 2 patients with progressive vestibular schwannoma. *Journal of Clinical Oncology* 2019; 37: 3446-54.
122. Kong N, Tao W, Ling X, Wang J, Xiao Y, Shi S, Ji X, Shajii A, Gan ST, Kim NY, **Duda DG**, Xie T, Farokhzad OC, Shi J. Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition. *Science Translational Medicine* 2019; 11, eaaw1565.
123. Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, **Duda DG**. Dual PD-1 and VEGFR-2 blockade promotes vascular normalization and enhances anti-tumor immune responses in HCC. *Hepatology* 2020; 71: 1247-61.

124. Leone JP, **Duda DG**, Hu J, Barry WT, Trippa L, Gerstner ER, Jain RK, Tan S, Lawler E, Winer EP, Lin NU, Tolaney SM. A Phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. *Breast Cancer Research* 2020; 179: 113-23.
125. Gerstner ER, Emblem KE, Chang K, Vakulenko-Lagun B, Yen Y-F, Beers A, Dietrich J, Plotkin SR, Catana C, Hooker J, **Duda DG**, Rosen B, Kalpathy-Cramer J, Jain RK, Batchelor TT. Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma. *Clinical Cancer Research* 2020; 26: 206-12.
126. Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S, Nojiri T, Ho, WW, Aoki S, Jung K, Chen I, Shi F, Heather JM, Shigeta K, Morton LT, Sepulveda S, Wan L, Joseph R, Minogue E, Khatri A, Bardia A, Ellisen LW, Corcoran RB, Hata A, Pai SI, Jain RK, Fukumura D, **Duda DG**, Cobbold M. Reprogramming antigenicity through selective delivery of peptide payload corrects antigen-repertoire mismatch in cancer. *Nature Biotechnology* 2020; 38: 420-5.
127. Mpekrisa F, Voutouria C, Baish JW, **Duda DG**, Munn LL, Stylianopoulos T, Jain RK. Combining normalization strategies to improve cancer immunotherapy. *Proceedings of the National Academy of Science USA* 2020; 117: 3728-37.
128. Kongpetch S, Jusakul A, Lim JQ, Ng CCY, Chan JY, Rajasegaran V, Lim TH, Lim KH, Choo SP, Dima S, Popescu I, **Duda DG**, Kukongviriyapan V, Khuntikeo N, Pairojkul C, Rozen SG, Tan P, Teh BT. Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma. *JCO Global Oncology* 2020; 6: 628-38.
129. **Duda DG**, Dima SO, Cucu D, Sorop A, Klein S, Ancukiewicz M, Kitahara S, Iacob S, Bacalbasa N, Tomescu D, Herlea V, Tanase C, Croitoru A, Popescu I. Potential Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients. *Cancers* 2020; 12: 1275.
130. Nagalo BM, Breton CA, Zhou Y, Arora M, Bogenberger JM, Barro O, Steele MB, Jenks NJ, Baker AT, **Duda DG**, Roberts LR, Russell SJ, Peng KW, Borad MJ. Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers. *Molecular Therapy: Oncolytics* 2020; 18: 546-55.
131. Goyal L, Sirard C, Schrag M, Kagey M, Eads J, Stacey S, El-Khoueiry A, Gulam M, Abrams T, Alok KA, Rebecca M, Devalingam M, Zhu AX, **Duda DG**. Phase 1 and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. *Clinical Cancer Research* 2020; 26: 6158-67.
132. Abdel-Wahab R, Hassan MM, Xiao L, Lacin S, Yalcin S, Shalaby AS, Al-shamsi HO, Raghav K, Wolff RA, Yao JC, Girard L, **Duda DG**, Dima S, Popescu I, Elghazaly HA, Vauthey J-N, Aloia TA, Conrad C, Chun YS, Tzeng C-W, Rashid A, Link JT, Sen S, George B, Amin HM, Morris JS, Kaseb AO. Impact of Integrating IGF-1 into MELD Score on Survival Prediction in Hepatocellular Carcinoma patients. *Oncology* 2020; 98: 836-46.
133. Shigeta K, Matsui A, Kikuchi H, Klein S, Mamessier M, Chen I, Aoki S, Kitahara S, Inoue K, Shigeta A, Hato T, Ramjiawan RR, Staiculescu D, Zopf D, Fiebig L, Quass A, Dima S, Popescu I, Huang P, Munn LL, Cobbold M, Goyal L, Zhu AX, Jain RK, **Duda DG**. Regorafenib increases T-cell infiltration when combined with PD1 blockade by inducing CXCL10 expression in HCC in mice. *Journal of Immunotherapy for Cancer* 2020; 8(2): e001435.
134. Gerstner ER, Emblem KE, Yen Y-F, Dietrich J, Jordan JT, Catana C, Wenchin KL, Hooker J, **Duda DG**, Rosen BR, Kalpathy-Cramer J, Jain RK, Batchelor TT. Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. *Neuro-Oncology Advances* 2020; (2)1: vdaa157.
135. Nayak L, Peters K, Clarke J, Jordan J, de Groot J, Nghiumphu L, Kaley T, Colman H, McCluskey C, Smith TR, Severgnini M, **Duda DG**, Muzikansky A, Molinaro A, Jain RK, Wen PY, Reardon DA. Phase II and biomarker study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma patients. *Clinical Cancer Research* 2021; 27: 1048-57.

136. Ajdari A, Xie Y, Richter C, Niyazi M, **Duda DG**, Hong S, Bortfeld T. Towards Personalized Radiation Therapy of Liver Metastasis: Added Predictive Value of Serial Blood Biomarkers. *JCO Clinical Cancer Informatics* 2021; 5: 315-25.
137. Aoki S, Inoue K, Klein S, Halvorsen S, Chen J, Matsui A, Nikmaneshi MR, Kitahara S, Hato T, Chen X, Kawakubo K, Tavakoli Nia H, Chen I, Sassi S, Schanne DH, Mamessier E, Shigeta K, Kikuchi H, Ramjiawan RR, Schmidt TCE, Iwasaki M, Yau T, Hong TS, Quaas A, Plum PS, Dima S, Popescu I, Bardeesy N, Munn LL, Borad MJ, Jain RK, Zhu AX, **Duda DG**. Placental growth factor increases tumor invasion and desmoplasia in intrahepatic cholangiocarcinoma and promotes treatment-resistance. *Gut* 2021; ePub on Jan 11, 2021 as doi: 10.1136/gutjnl-2020-322493.
138. Mohamed Y, Lee S, Xiao L, Hassan M, Qayyum A, Hiatia R, Carmagnani Pestana R, Amin H, Haque A, George B, Rashid A, **Duda DG**, Elghazaly H, Wolff R, Morris J, Yao J, Kaseb A. Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. *Oncotarget* 2021; 12: 756-66.
139. Li W, Li S, Liu Y, Ramjiawan RR, Leung C-H, Gerweck LE, Fukumura D, Loeffler JS, Jain RK, **Duda DG**, Huang P. Combining Losartan with Radiotherapy Increases Tumor Control and Inhibits Metastases from HER2/neu-positive Orthotopic Breast Cancer Model. *Radiation Oncology* 2021; 16: 48.
140. Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydłowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Stirn K, Kosla J, Kotsiliti E, Leone V, Dudek V, Youssuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratzu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, De Dosso S, Mallm J-P, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Augustin HG, Billeter A, Müller-Stich B, Kikuchi H, **Duda DG**, Kütting F, Waldschmidt D-T, Ebert MP, Rahbari N, Wolter K, Zender L, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour J-F, Marron TU, Kaseb A, Kudo M, Huang Y-H, Djouder N, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M. NASH precludes anti-tumor surveillance in HCC-immunotherapy. *Nature* 2021; 592: 450-6.
141. Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott K, Bezwada D, Blanc L, Prideaux B, Possada J, Chen J, Chin C, Amoozgar Z, Ferriera R, Chen I, Naxerova K, Jin X, Ng C, Westermarck A, Davidson S, Lyssiotis C, Nielsen J, Housman D, **Duda DG**, Brachtel E, Gollub TR, Engelman JA, Cantley LC, Asara J, Fukumura D, Dartois V, Clish CB, Jain RK, Vander Heiden MG. Fatty acid synthesis is required for breast cancer brain metastasis. *Nature Cancer* 2021; ePub on April 1, 2021 10.1038/s43018-021-00183-y.
142. Barroso-Sousa R, Keenan TE, Li T, Tayob N, Trippa L, Pastorello RG, Richardson III ET, Dillon D, Overmoyer B, Amoozgar Z, Schnitt SJ, Winer EP, Mittendorf EA, Van Allen E, **Duda DG\***, Tolaney SM\*. Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: A phase II and biomarker study. *npj Breast Cancer* 2021 (in press). \*Co-senior authors.
143. Boucher Y, Kumar AS, Posada JM, Gjini E, Pfaff K, **Duda DG**, Rodig S, Hodi FS, Jain RK. Bevacizumab Improves Tumor Infiltration By Mature Dendritic Cells and Effector T-cells in Triple-Negative Breast Cancer Patients. *npj Precision Oncology* 2021 (accepted).

#### **Non-peer reviewed scholarship in print or other media:**

#### **Proceedings of meetings or other non-peer reviewed scholarship**

144. **Duda DG**. Anti-angiogenesis and drug delivery in tumors: Bench to bedside and back. *Cancer*

**Research.** 2006; 66: 3967-70.

145. Woodward WA, Bristow RG, Clarke MF, Coppes R, Cristofanilli M, **Duda DG**, Fike JR, Hambardzumyan D, Hill R, Jordan CT, Milas L, Pajonk F, Curran W, Dicker A, Chen Y. Radiation therapy Oncology Group Translational Research Program Stem Cell Symposium: Incorporating stem cell hypothesis into clinical trials. *International Journal of Radiation Oncology, Biology and Physics* 2009; 74: 1580-91.
146. Stroh M, **Duda DG**, Takimoto CH, Yamazaki S, Vicini P. Translation of anticancer efficacy from nonclinical models to the clinic. *Clinical Pharmacology and Therapeutics: Pharmacometrics and Systems Pharmacology* 2014; 3: e128.
147. Pantziarka P, Hutchinson L, André N, Benzekry S, Bertolini F, Bhattacharjee A, Chiplunkar S, **Duda DG**, Gota V, Gupta S, Joshi A, Kannan S, Kerbel R, Kieran M, Palazzo A, Parikh A, Pasquier E, Patil V, Prabash K, Shaked Y, Saulnier Sholler G, Sterba J, Waxman D, Banavali S. Next Generation Metronomic Chemotherapy – Report from the 5th Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6th – 8th May 2016, Mumbai. *Ecancermedicalscience.* 2016; 10: 689.

### Reviews, chapters, monographs and editorials

148. Son L, Sunamura M, **Duda DG**, Lozonschi L, Matsuno S. The antiangiogenesis effect of IL-12 on human pancreatic cancer. In: *Carcinoma of the Pancreas and Biliary Tract* Sendai: Tohoku University Press. Wakui A, Yamauchi H, Ouchi K, editors. 1999; 273-9.
149. Sunamura M, **Duda DG**, Lozonschi L, Son L, Takeda K, Matsuno S. Controlling tumor microenvironment by the antiangiogenesis strategy. In: *Trends in Gastroenterology and Hepatology* Tokyo: Springer-Verlag. Asakura H, Aoyagi Y, Nakazawa S, editors. 2001; 287-9.
150. Sunamura M, Yatsuoka T, Motoi F, **Duda DG**, Kimura M, Abe T, Yokoyama T, Inoue H, Oonuma M, Takeda K, Matsuno S. Gene therapy for pancreatic cancer based on genetic characterization of the disease. *Journal of Hepatobiliary and Pancreatic Surgery* 2002; 9: 32-8.
151. Jain RK, **Duda DG**. Role of bone marrow-derived cells in tumor angiogenesis and treatment. *Cancer Cell* 2003; 3:515-6.
152. **Duda DG**, Fukumura D, Jain RK. Role of eNOS in neovascularization: NO for endothelial progenitor cells. *Trends in Molecular Medicine* 2004; 10:143-5.
153. Jain RK, Au P, Tam J, **Duda DG**, Fukumura D. Engineering vascularized tissue. *Nature Biotechnology* 2005; 23: 821-3.
154. **Duda DG**, Jain RK. Pleiotropy of tissue-specific growth factors: from neurons to vessels via the bone marrow. *Journal of Clinical Investigation* 2005; 115: 596-8.
155. Jain RK, **Duda DG**, Clark JW, Loeffler JS. Lessons from Phase III clinical trials of anti-VEGF therapy for cancer. *Nature Clinical Practice Oncology* 2006; 3: 24-40.
156. Willett CW, Kozin SV, **Duda DG**, di Tomaso E, Kozak KR, Boucher Y, Jain RK. Combined Vascular Endothelial Growth Factor–targeted therapy and radiotherapy for colorectal cancer: Theory and clinical practice. *Seminars in Oncology* 2006; 33: S35-S40.
157. Willett CG, **Duda DG**, Jain RK. Surrogate biomarkers for anti-angiogenic therapy for advanced colorectal cancer. *Current Colorectal Cancer Reports* 2007; 3: 94-8.
158. **Duda DG**, Willett CG, Jain RK. The current progress, hurdles and future prospects in anti-VEGF targeted cancer therapy strategies. *Trends in Molecular Medicine* 2007; 13: 223-30. PMID: PMC2686126.
159. Jain RK, Tomaso E, **Duda DG**, Sorensen AG, Loeffler JS, Batchelor TT. Angiogenesis in brain tumors. *Nature Reviews in Neuroscience* 2007; 8: 610-22.
160. Willett CG, **Duda DG**, Czito BG, Bendell J, Clark JF, Jain RK. Targeted therapy in rectal cancer. *Oncology* (Williston Park) 2007; 21: 1055-65.
161. **Duda DG**, Jain RK, Willett CG. Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers. *Journal of Clinical Oncology* 2007; 25: 4033-42.

162. Gerstner ER, **Duda DG**, di Tomaso E, Sorensen AG, Jain RK, Batchelor TT. Angiogenesis-targeting agents for the treatment of glioblastoma. *Expert Opinion on Investigational Drugs* 2007; 16: 1895-908.
163. Perentes JY, **Duda DG**, Jain RK. Visualizing anti-tumor immune responses in vivo. *Disease Models and Mechanisms* 2009; 2: 107-10.
164. Gerstner ER, **Duda DG**, di Tomaso E, Ryg PA, Loeffler JS, Sorensen AG, Ivy P, Jain RK, Batchelor TT. The potential utility of anti-VEGF agents to normalize tumor vasculature and alleviate edema in brain and spinal cord tumor patients. *Nature Reviews Clinical Oncology* 2009; 6: 229-36.
165. Jain RK, **Duda DG**, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG. Biomarkers of response and resistance to antiangiogenic therapy in cancer. *Nature Reviews Clinical Oncology* 2009; 6: 327-38. PMID: PMC3057433.
166. Zhu AX, **Duda DG**, Sahani DV, Jain RK. Development of sunitinib in hepatocellular carcinoma: Rationale, early clinical experience and correlative studies. *Cancer Journal* 2009; 15: 263-8.
167. Fukumura D, **Duda DG**, Munn LL, Jain RK. Tumor microvasculature and microenvironment: Novel insights through intravital imaging in pre-clinical models. *Microcirculation* 2010; 17: 1-19.
168. **Duda DG**, Jain RK. Pre-metastatic lung “niche”: Is VEGFR1 activation required? *Cancer Research* 2010; 70: 5670-3.
169. **Duda DG\***, Kozin SV, Kirkpatrick N, Xu L, Fukumura D, Jain RK\*. CXCL12 (SDF1 $\alpha$ ) pathway inhibition: A new sensitizer for anti-cancer therapies? *Clinical Cancer Research* 2011; 17: 2074-80. PMID: PMC3079023. \* Corresponding authors.
170. Zhu AX, **Duda DG**, Sahani DS, Jain RK. HCC and angiogenesis: possible targets and future directions. *Nature Reviews Clinical Oncology* 2011; 8: 292-301.
171. Goel S, **Duda DG**, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. *Physiological Reviews* 2011; 91: 1071–121.
172. Kozin SV, **Duda DG**, Munn LL, Jain RK. Neovascularization after irradiation: What is the source of newly formed vessels in recurring tumors? *Journal of the National Cancer Institute* 2012; 104: 899-905. PMID: PMC3379722.
173. Huang Y, Goel S, **Duda DG**, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. *Cancer Research* 2013; 73: 2943-8.
174. Hato T, Goyal L, Gretten TF, **Duda DG\***, Zhu AX\*. Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions. *Hepatology* 2014; 60: 1776-82. \*Corresponding authors.
175. Richter C, Seco J, Hong TS, **Duda DG**, Bortfeld T. Radiation-induced changes in hepatocyte-specific Gd-EOB-DTPA enhanced MRI: Potential mechanism. *Medical Hypotheses* 2014; 83: 477-81.
176. Lu-Emerson C\*, **Duda DG\***, Emblem KE, Taylor JW, Gerstner ER, Batchelor TT, Jain RK. Lessons from antiangiogenesis trials in glioblastoma patients. *Journal of Clinical Oncology* 2015; 33: 1197-213. \* Equal contribution.
177. Setia N, Clark JW, **Duda DG**, Hong TS, Kwak E, Mullen JT, Lauwers GY. Familial gastric cancers. *Oncologist* 2015; 20: 1365-77.
178. Samuel R, **Duda DG**, Fukumura D, Jain RK. Vascular diseases await translation of blood vessels engineered from stem cells. *Science Translational Medicine* 2015; 7: 309rv6.
179. Gupta N, **Duda DG**. Role of Stromal Cell-Derived Factor 1 $\alpha$  Pathway in Bone Metastatic Prostate Cancer. *Journal of Biomedical Research* 2016; 30: 181-185.
180. Hato T, Zhu AX, **Duda DG**. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. *Immunotherapy* 2016; 8: 299-313.
181. Popp I, Niedermann G, Grosu AL, **Duda DG**. Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. *Radiotherapy and Oncology* 2016; 120: 185-94.
182. Ali M, Lacin S, Ali R, Uemura M, Hassan M, Rashid A, **Duda DG**, Kaseb A. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: Is there a role of the androgen receptor pathway? *OncoTargets and Therapy* 2017; 10: 1403-1412.
183. Ramjiawan RR, Griffioen AW, **Duda DG**. Anti-angiogenesis for cancer revisited: Is there a role

- for combinations with immunotherapy? *Angiogenesis* 2017; 20: 185-204.
184. Yokoda R, Nagalo BM, Vernon B, Oklu R, Albadawi H, DeLeon T, Zhou Y, Egan J, **Duda DG**, Borad MJ. Oncolytic virus delivery: from nanopharmacodynamics to enhanced oncolytic effect. *Oncolytic Virotherapy* 2017;6 1–11.
  185. Fukumura D, Kloepper J, Amoozgar Z, **Duda DG**, Jain RK. Enhance cancer immunotherapy using antiangiogenics: opportunities and challenges. *Nature Reviews Clinical Oncology* 2018; 15: 325-40.
  186. **Duda DG**, Aoki S, Dima S, Popescu I, Borad MJ. Novel biomarkers in cholangiocarcinoma. *Surgery, Gastroenterology and Oncology* 2018; doi: 10.21614/sgo-23-4-259.
  187. Jain RK, **Duda DG**. Angiogenesis in solid tumors. In: *Antiangiogenic Cancer Therapy*, CRC Press, Boca Raton. Abbruzzese JL, Davis DW, Herbst RS, editors. 2007; pp: 43-90.
  188. Willett CG, **Duda DG**. Combined modality therapy of rectal cancer. In: *Antiangiogenic Cancer Therapy*, CRC Press. Abbruzzese JL, Davis DW, Herbst RS, editors. 2007; pp: 549-57.
  189. Jain RK, **Duda DG**. Normalization of tumor vasculature and microenvironment by antiangiogenic therapy. In: *Tumor Angiogenesis: Mechanisms and Cancer Therapy*, Springer-Verlag. Marmé D, Fusenig NE, editors. 2007; pp: 577-92.
  190. **Duda DG**. [Commentary] Angiogenesis and anti-angiogenesis in cancer. *iDrugs*. 2007; 10: 366-9.
  191. Jain RK, Batchelor TT, **Duda DG**, Willett CG. Normalization of tumor vasculature and microenvironment, In: *Antiangiogenic Agents In Cancer Therapy*. Second Edition, Humana Press. Teicher B and Ellis L, editors. 2007; pp: 261-76.
  192. **Duda DG**. [Editorial] Endothelial cell-based therapy for hematopoiesis. *Blood* 2007;109: 2272-3.
  193. Jain RK, **Duda DG**, Batchelor TT, Sorensen AG, Willett CG. Normalization of tumor vasculature and microenvironment. In: *Angiogenesis: An Integrative Approach from Science to Medicine* Springer. Figg WD and Folkman J, editors. 2008; pp: 267-75.
  194. Jain RK, **Duda DG**. Vascular and interstitial biology of tumors. In: *Clinical Oncology* Fourth Edition, Elsevier, Philadelphia. Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna WG, editors. 2008; pp: 105-24.
  195. **Duda DG**. Antiangiogenesis. In: *Encyclopedia of Cancer*. Second Edition, Springer-Verlag. Schwab M, editor. 2008; Part 1; pp: 184-8.
  196. Jain RK, **Duda DG**, Sorensen AG. Emerging paradigms and potential biomarkers of response and resistance in antiangiogenic therapy of cancer. *ASCO Educational Book* 2009; pp 716-21.
  197. **Duda DG**, Ancukiewicz MA, Jain RK. Biomarkers of antiangiogenic therapy: How do we move from candidate biomarkers to valid biomarkers? *Journal of Clinical Oncology* 2009; 28: 183-5.
  198. **Duda DG**. Targeting Tumor Angiogenesis: Biomarkers of Angiogenesis and Antiangiogenic Therapy in Cancer. e-publication, Angiogenesis Foundation, 2011 (CME, August 30, 2011).
  199. **Duda DG**. Antiangiogenesis. In: *Encyclopedia of Cancer*. Third Edition, Springer-Verlag. Schwab M, editor; (2012).
  200. **Duda DG** and Willett CG. [Editorial] Going beyond systemic fluoropyrimidine with radiation therapy for rectal cancer: What should be the priority? *Oncology* (Williston Park) 2012; 26: 741-3.
  201. Jain RK and **Duda DG**. Molecular Pathophysiology of Tumors. In: *Principles and Practice of Radiation Oncology*, 6<sup>th</sup> Edition (Editors: E. C. Halperin, C. A. Perez, L. W. Brady), Lippincott, Williams & Wilkins, New York, Chapter 4 (2013), pp 102-117.
  202. **Duda DG**. Molecular biomarkers of response to antiangiogenic therapy for cancer. *ISRN Cell Biology*; 2012, Article ID 587259, doi:10.5402/2012/587259.
  203. **Duda DG** and Willett CG. [Expert Editorial] Reassessing priorities in the management of locally advanced rectal cancer: The need for new biomarkers and targets. *Gastrointestinal Cancers Symposium Daily News* Thursday, January 24, 2013: pp 22-23.
  204. **Duda DG**. Biomarkers of response and resistance to antiangiogenic treatment. In: *Angiogenesis Modulations in Health and Disease*, First Edition, Springer. Mousa, SA, Davis PJ, editors. 2013; Chapter 15, pp 181-198.

205. **Duda DG**, Munn LL, Jain RK. [Editorial] Can we identify predictive biomarkers for anti-angiogenic therapy of cancer using mathematical modeling? *Journal of the National Cancer Institute* 2013; 105: 762-765.
206. Jain RK, Chauhan V, **Duda DG**. Vascular and interstitial biology of tumors. In: *Clinical Oncology* Fifth Edition, Elsevier, Philadelphia. Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna WG, editors. 2013; pp 108-126.
207. Bucur O, Almasan A, Nikolajczyk BS, Nicolson GL, Lawler J, Velculescu VE, Leabu M, Avram D, Bucur I, Calin GA, Carbonetto S, Chauhan SC, Ciubotaru M, Constantinescu SN, Datta D, Draghici S, **Duda DG**, Friedman MT, Galardy PJ, Harris BT, Huarte M, Khalil AM, Marchetti D, Movileanu L, Nat R, Nucera C, Popa-Wagner A, Stancu AL, Zhu S, Liehn AL. [Editorial] Discoveries: an innovative platform for publishing cutting-edge research discoveries in medicine, biology and chemistry. *Discoveries* 2013; 1: e1.
208. Jain RK, Fukumura D, **Duda DG**. Modes of neovascularization in tumors and clinical translation of antiangiogenic therapy. In: *Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms*. First Edition, San Diego: Elsevier Inc. McManus LM and Mitchell RN, editors. 2014; p. 2926-2957.
209. **Duda DG** and Hong TS. [Expert Editorial] Perioperative use of radiation therapy in localized pancreatic adenocarcinoma. *Gastrointestinal Cancers Symposium Daily News* Friday, January 17, 2014, Issue 2: pp 1, 6, 13.
210. **Duda DG**, Ancukiewicz MA, Isakoff SJ, Krop IE, Jain RK. [Editorial] Seeds and Soil: Unraveling the Role of Local Tumor Stroma in Distant Metastasis. *Journal of the National Cancer Institute* 2014; 1; 106: pii: dju187.
211. Jain RK, Fukumura D, **Duda DG**. [Editorial] Lessons from thirty years of teaching about the microenvironment of tumors. *Cancer Journal* 2015; 21: 137.
212. Chen Y, **Duda DG**. [Commentary] Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma – an auto-commentary on clinical potential and future development. *Oncoimmunology* 2015; 9:4, e1029703.
213. Jain RK, Fukumura D, **Duda DG**. [Introduction] Role of tumor microenvironment in tumor progression and treatment response: A 30-years journey. *Cancer Journal* 2015; 21: 235-6.
214. Goyal J, Ye X, **Duda DG**, Zhu AX. [Commentary] Chemotherapy and antiangiogenics in biliary tract cancer. *Lancet Oncology* 2015; 16: 882-3.
215. Duda DG, Takaori K, Makuuchi M. A new beginning. *Journal of Translational Medicine and Research* 2016; 21: 5-6.
216. Martin JD, Fukumura D, **Duda DG**, Boucher Y, Jain RK Reengineering the tumor microenvironment to alleviate hypoxia and overcome cancer heterogeneity. *Cold Spring Harbor Laboratory Perspectives in Medicine*; 2016; pii: a027094.
217. Shigeta K, Hato T, Chen Y, **Duda DG**. Anti-VEGFR therapy as a partner for immune-based therapy approaches in HCC. In: *Immunotherapy of Hepatocellular Carcinoma*. First Edition, Springer Inc. Greten T, editor. 2017; 85-102.
218. Aoki S, Cobbold M, Zhu AX, **Duda DG**. [Editorial] Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage? *Hepatology* 2017; 67: 826–8.
219. Rahbari NN, **Duda DG**, Borad MJ, Han H-S. Need for Consensus Statement for Cholangiocarcinoma Diagnosis, Prognostication and Treatment: An IASGO Initiative. *Surgery, Gastroenterology and Oncology* 2018; doi: 10.21614/sgo-23-4-217.
220. Jain RK, Martin JD, Chauhan VP and **Duda DG**. Molecular Pathophysiology of Tumors. In: *Principles and Practice of Radiation Oncology*, 7<sup>th</sup> Edition (Editors: E. C. Halperin, C. A. Perez, L. W. Brady), Lippincott, Williams & Wilkins, New York, Chapter 4 (2019).
221. Schanne D, Grosu A-L, **Duda DG**. Anti-Angiogenics and Radiation Therapy. In: *Tumor Angiogenesis: A Key Target for Cancer Therapy*. First Edition, Springer. Marme D, editor. 2019; pp 349-358.



222. Amoozgar Z, Jain RK, **Duda DG**. Role of apelin in glioblastoma vascularization and invasion after anti-VEGF therapy: What is the impact on the immune system? *Cancer Research* 2019;79:2104–6.
223. Chen J, **Duda DG**. Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms. *EBioMedicine* 2020; 52: 102644.
224. Ho AY, Wright JL, Blitzblau RC, Mutter RW, **Duda DG**, Norton L, Bardia A, Spring L, Isakoff SJ, Chen JH, Grassberger C, Bellon JR, Beriwal S, Khan AJ, Speers C, Dunn SA, Thompson A, Santa-Maria CA, Krop IE, Mittendorf E, King TA, Gupta GP. Optimizing Radiotherapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. *International Journal of Radiation Oncology, Biology and Physics* 2020; 108: 227-41.
225. Martin JD, **Duda DG**, Jain RK. Going beyond VEGF pathway inhibition for antiangiogenic cancer therapy: Is inhibition of the PP2A/B55 $\alpha$  complex the answer? *Circulation Research* 2020; 127: 724-6.
226. Pinter M, Jain RK, **Duda DG**. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: A Review. *JAMA Oncology* 2021; 7: 113-23.
227. Hauth FD, Ho A, Ferrone S, **Duda DG**. Use of Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy of Solid Tumors: A Narrative Review. *JAMA Oncology* 2021, ePub on April 22, 2021 as doi: 10.1001/jamaoncol.2021.0168.
228. **Duda DG**, Hauth FD. Use of radiotherapy alone and in combination with other therapies for hepatocellular carcinoma: Rationale and future directions. In: *IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases*. First Edition, Springer-Nature. Makuuchi M, Kokudo N, Popescu I, Belghiti J, Han H-S, Takaori K, Duda DG, editors. **Springer Nature**. 2021; in press.
229. Klein S, **Duda DG**. Stromal composition phenotyping and diagnostic potential of machine learning in gastro-esophageal cancers. *Cancers* 2021; in press.
230. Tabrizi S, Dunn S, **Duda DG**, Ho AY. Current Advances in Radiation Therapy and Immune Checkpoint Inhibitor Combinations for Breast Cancer. *Frontiers in Oncology* 2021; in press.

### Case reports

231. Willett CG\*, **Duda DG**\*, di Tomaso E, Boucher Y, Czito BG, Bendell J, Cohen KS, Hurwitz HI, Bentley R, Wong TZ, Paulson E, Jain RK. Complete pathological response in T4 locally advanced rectal cancer after treatment with bevacizumab and standard radio-chemotherapy. *Nature Clinical Practice Oncology* 2007; 4: 316-21. \* Equal contribution.
232. Hagendoorn J, Padera TP, Yock TI, Nielsen GP, di Tomaso E, **Duda DG**, Delaney TF, Gaisert HA, Pearce J, Rosenberg AE, Jain RK, Ebb DH. Platelet derived growth factor  $\beta$  in Gorham's disease. *Nature Clinical Practice Oncology* 2006; 3: 693-7.

### Letters to the Editor

233. Willett CG, **Duda DG**, Fischman A, Jain RK. [Correspondence] Reply to: PET concerns in bevacizumab treatment. *Nature Medicine* 2004; 10: 561.
234. **Duda DG**, Cohen KS, Au P, Scadden DT, Willett CG, Jain RK. [Correspondence] Reply to: Detection of circulating endothelial cells: CD146-based magnetic separation enrichment or flow cytometric assay? *Journal of Clinical Oncology* 2007; 25: e3-e5.
235. Zhu AX, Sahani DV, **Duda DG**, Jain RK. [Correspondence] Reply to S.J. Faivre *et al.*: Sunitinib in hepatocellular carcinoma: Redefining appropriate dosing, schedule, and activity endpoints. *Journal of Clinical Oncology* 2009; 27: e251-2.
236. Kozin SV, **Duda DG**, Munn LL, Jain RK. [Correspondence] Is vasculogenesis crucial for the regrowth of irradiated tumours? *Nature Reviews Cancer* 2011; 11: 532.
237. **Duda DG**, Heist RS, Sahani DV, Stylianopoulos T, Engelman JA, Jain RK. [Correspondence] Reply to Ciccolini *et al.*: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients. *Proceedings of the National Academy of Science USA* 2015; 112: E3454.

238. Huang Y, Stylianopoulos T, **Duda DG**, Fukumura D, Jain RK. [Letter] Benefits of vascular normalization are dose- and time-dependent. Re: Bevacizumab hampers antibody uptake. *Cancer Research* 2013; 73: 7144-7146.

## Thesis:

**Duda DG**. Analysis of the pancreatic adenocarcinoma-related angiogenesis and evaluation of the effectiveness of antiangiogenic gene therapy. [Dissertation]. *Tohoku University Graduate School of Medicine Press*, Sendai, Japan, April 2001.

## Narrative Report

I am an investigator in the field of gastrointestinal (GI) cancer biology and therapy. After completing medical training in Romania (DMD 1993, residency 1997), I discovered my passion for basic and translational research during my PhD studies in GI Surgery at Tohoku University in Japan and my postdoctoral studies at Harvard. I chose research as my career path. The primary focus of my current research is overcoming treatment resistance in primary and metastatic liver cancers. To this end, my group is studying new combinatorial approaches using antiangiogenic and antifibrotic drugs or radiotherapy with immunotherapy using preclinical studies that reproduce the hallmarks of human cancers (using genetically engineered models of primary hepatocellular carcinoma and cholangiocarcinoma, and metastatic pancreatic carcinomas). In parallel, I am conducting comprehensive correlative studies in liver cancer patients in collaboration with clinicians. My work in the field has led to many findings on liver cancers and cancer metastasis. These studies are reported in 100+ peer reviewed original articles (more than half as a first or senior/corresponding author) and have been presented at 200+ local, national, and international meetings, including Grand Rounds (Harvard, Mayo Clinic, Yale, Fred Hutch), Plenary Talks at meetings of the American Association for Cancer Research (AACR), International Society for Stem Cell Research (ISSCR), International Association of Surgeons, Gastroenterologists and Oncologists (IASGO) and multiple Keynote Lectures. As a result of my accomplishments in translational research, I was appointed as the Director of GI Radiation Oncology at MGH in 2016. I am a Founding Editor of the IASGO's official journal *Surgery, Gastroenterology and Oncology*, a Senior Associate Editor of the *International Journal of Radiation Oncology\*Biological\*Physics*, and an Editorial Board member for several other journals. I have been serving as the executive leader (Secretary General) of IASGO since 2015. In addition, I am a member of the American Association for the Study of Liver Diseases (AASLD) Liver Fibrosis Group Global Outreach Committee since 2019, and of NCI's Hepatobiliary Task Force for Immuno-Oncology Biomarkers since 2020. I have been serving as chartered Panel Member and Chair of NCI, American Cancer Society (ACS) and Research Foundation Flanders (FWO) study sections since 2012, and ad-hoc reviewer more than 20 other agencies from 12 countries. I served in expert advisory roles for Pharma and in Liver Cancer Expert meetings in Seoul, Korea (2018), Verona, Italy (2019), and Sapporo, Japan (2019). Since 2019, I serve as an advisor to the MD Anderson Center of Excellence Program for HCC. I organized and chaired national and international symposia on Liver Cancer topics at Mayo Clinic (since 2019), in Rotterdam, The Netherlands (2017), Luzhou, China (2017 and 2019), Braga, Portugal (since 2019) Istanbul, Turkey (2020) and Taipei, Taiwan (2021). For my work, I have received several profession awards and honors. Among these, I became an Honorary Member of the Academy of Medical Sciences of Romania in 2012 and was elected a member of the College of Fellows of AIMBE – considered to represent the top 2% of the most accomplished leaders in the fields of medical and biological engineering – in 2020.

Over the last decade and a half, I have built a vibrant and dynamic Liver Cancer Research Program within the Steele Laboratories for Tumor Biology at MGH. True to my passion and medical training, I have enjoyed participating in large multidisciplinary research efforts with my postdoctoral mentor Dr. Jain and clinician-scientists at MGH and other institutions. As an Assistant Professor, I have carved out a main area of research focused on liver tumor interaction with its microenvironment and its impact on resistance to immune, antiangiogenic and cytotoxic therapies since 2008. The translational goal of my program is increasing the durability of response to the most effective available molecular and cellular therapies. The research goal is to identify new cellular and molecular mechanisms of local and metastatic tumor progression and treatment resistance and validate them as new targets for treatment. For my independent research, I received support from the NCI (an R21 grant in 2009, an R01 grant and a Proton Beam Federal Share Individual Grant in 2011, and a PPG Project in P01 grant in 2012) and from the ACS (a Research Scholar Grant in 2011). Since then, I received continuous funding as a PI through diverse research mechanisms, including multiple R01 grants from NIH, Department of Defense Awards and sponsored research agreements with Industry totaling more than US\$15M so far. When I started working in this area, there was no systemic therapy available for patients with advanced liver cancer, and radiotherapy was rarely used for these diseases due to concerns related to liver toxicity. Patients with advanced hepatocellular carcinoma (HCC), the most frequent liver cancer, received “best supportive care” and lived 6 months on average. Preclinical data were severely limited by the lack of models of liver cancer with underlying liver damage, the typical presentation of HCC in patients. Today, liver cancer therapy has become one of the most active and exciting areas of research, with 6 antiangiogenic drugs and 3 immune checkpoint blocking drugs approved by the US FDA for HCC treatment, and with proton radiotherapy being tested in a pivotal phase III trial led by our MGH team. My contribution to this worldwide effort has been both in clinical translational studies and preclinical studies. Inspired by the correlative studies published in the *Journal of Clinical Oncology* in 2009, the first report of biomarkers of response to standard anti-vascular endothelial growth factor receptor (VEGFR) therapy in HCC, I postulated that treatment-induced modulation of inflammatory factors and functional changes in the vasculature may be responsible for treatment resistance in HCC. These findings—along with subsequent clinical reports on VEGF inhibitors published in *Clinical Cancer Research* (2011, 2013, 2013 and 2016)—opened a new preclinical research direction in my lab. For this, I established unique models of spontaneous HCC in mice with underlying liver damage resembling human disease (*Nature Protocols* 2015) and revealed mechanisms underlying anti-VEGFR treatment response and resistance in models that reproduced hallmark of human disease. The work defined the role of myeloid-derived suppressor cells and SDF1 $\alpha$ /CXCR4 chemokine pathway-mediated changes after sorafenib treatment in the fibrotic and inflammatory tumor environment of advanced HCCs (*Hepatology* 2014). At that time, it became apparent that immune checkpoint blockade will transform systemic therapy for cancer. I conducted the first study of an anti-VEGFR/anti-PD-1 combination in HCC models, which revealed that successful implementation of this strategy in HCC will depend on appropriate polarization of the immune microenvironment to allow cytotoxic T lymphocytes to infiltrate the tumor tissue and function (*Hepatology* 2015). More recently, in a study reported in *Hepatology* (2020), my group uncovered an unexpected mechanism of synergy for this combination therapy: PD-1 blockade led to “productive”, normal new vessel formation in the regressing tumors, and the normalized vasculature enhanced the anti-tumor immune responses. Subsequently, a pivotal randomized phase III study demonstrated the efficacy of dual VEGF/PD-L1 blockade in HCC patients by showing unprecedented benefits over the standard of care (sorafenib) (Finn *et al.*, *New England Journal of Medicine* 2020). The FDA approved this antibody-based combination therapy as first line of treatment for HCC on May 29, 2020. In 2021, I received an R01 grant to study the role of dual VEGF/PD-L1 blockade in early-stage HCC. Another example is the discovery of plasma HGF as a potential biomarker of susceptibility to radiation-induced liver damage (RILD), currently being tested as an integrated biomarker in a randomized phase III trial (NCT03186898). In parallel, I study the role of HGF/MET axis in RILD using state of the art models of liver damage and cancer in mice supported by a DOD Peer-Reviewed Cancer Program Impact Award since 2019. I have used these findings and grants to start many projects on HCC (*Science Translational Medicine* 2019, *Nature Biotechnology* 2020, *Nature* 2021,

supported by the DOD and Industry) and other liver cancers, including studies on cholangiocarcinoma (e.g., *Nature Genetics* 2013, *Cancer Discovery* 2016, *Clinical Cancer Research* 2021 and *Gut* 2021, supported by the DOD) and targeting micrometastatic/occult pancreatic cancer (e.g., *International Journal of Radiation Oncology\*Biological\*Physics* 2014; *JAMA Oncology* 2019, with NIH R01 support).

I am teaching tumor biology and translational oncology through daily supervision of postdoctoral research fellows, and graduate and undergraduate students. As a passionate supporter of the IASGO's mission to globalize the best medical practice and knowledge all over the world, I have been coordinating, teaching, and directing Postgraduate Courses in 28 countries in Asia, Europe, Africa, and the Americas, since 2014. I have also taught nationally in ASTRO and RTOG translational meetings for residents and clinicians and locally in the MIT-HMS HST Program since 2005. I have been coordinating a research exchange student program with University of Muenster, Germany since 2015, and I have been directing an Annual Course titled "*Methods in Biomedical Engineering, Tumor Biology and Immunology*" for trainees at MGH since 2004. In addition to teaching of students, I have continuously advocated for increased support for research in the treatment of advanced cancers in the community at large. My community outreach efforts included volunteering as a speaker for several Relay for Life Training Programs, Fight Back Ceremony and Bicycles Battling Cancer ride and other Fundraisers for the Massachusetts ACS Division, as well as participating at private fundraisers such as Kathy's Gala of Hope organized by Granara-Skerry Trust. In recognition of my achievements in research, teaching, leadership, and advocacy, I was selected as an Honoree of The One Hundred in 2015. Selection as an honoree of the one hundred was one of the highest forms of recognition awarded by Mass General Cancer Center. I also received the Heroes of Hope Award for Cancer Research from the Granara-Skerry Trust in 2016, and the 2020 Excellence Award - World Ambassador of Romanian Medicine from the Romanian Academy and Medica Academica, Tarus Media, Romania in 2020.

I am dedicated to the pursuit of impactful and translational research in the field of GI malignancies. While recent progress has changed the treatment landscape in a tangible way, effective therapy or cure for these dreadful diseases remains an unmet need. I am passionate about engaging the joint efforts of scientist and clinician collaborators and continuing my strong commitment to educate the next generation of thought leaders through mentoring and multidisciplinary training at MGH, Harvard-wide, and worldwide.